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ABSTRACT 
Reasons for the observed lag-time for clinical efficacy of the 
tricyclic antidepressant drug, protriptyline, have been investigated. 
t-, 
• 
Our results demonstrate that chronic protriptyline administration resulta 
in several compensatory neural mechanisms: (1) changes in endogeneous 
cytoplasmic norepinephrine levels, (2) changes in norepinephrine turnover 
rate/recovery rate following the last dose in a chronic series of test 
drug administrations and (3) adaptations of the pre-synaptic receptor. 
The time course for these adaptive changes parallel the time required 
for the onset of their clinical effectiveness. 
We propose that acutely the action of the tricyclics on norepinephrine 
re-uptake is largely negated by compensatory adjustments in turnover rate 
of the neurotransmitter; but with chronic administration, adaptations in 
pre-synaptic alpha-receptors occur. This phenomena in turn reduces 
the extent to which the norepinephrine neurons can offset or compensate 
for the blockade of norepinephrine re-uptake. Specifically, pre-synaptic 
alpha-receptors become hyposensitive, and receptor tolerance develops; 
not to the direct action of the tricyclic drug on neurotransmitter 
re-uptake, but to the compensatory neural adjustments which offset the 
action of the acute tricyclic administration and delay their clinical 
efficacy. 
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PREFACE 
In the last 25 years many observations have documented the 
suggestion that a relationship exists between central norepinephrine 
function and affective disorders. The catecholamine hypothesis of 
affective disorders is one theory advanced by researchers. It propos• 
that some, if not all depressions are associated with an absolute or 
relative deficiency of catecholamines, in particular norepinephrine (ME), 
at the functionally important adrenergic receptor sites in the brain. 
The tricyclic antidepressants (TCA), which normalize a depressed mood, 
block the active re-uptake of norepinephrine after release frOll the 
presynaptic nerve terminals. Thus both the ti.me and the concentration 
of norepinephrine availability is increased in the synaptic cleft for 
post-synaptic attachment. It is likely, however, that the ability of 
the tricyclics to block norepinephrine re-uptake, though the primary 
mechanism of action, may not be the only mechanism involved. This is 
evident frOll the observation that re-uptake blockade of NE by the tri-
cyclics occurs within minutes after their administration; however, 
clinical efficacy in patients is not obvious until these drugs have 
been administered chronically (10-20 days). This observed lag-time 
for clinical efficacy suggests the existence of an alternate mechanisa 
of action for this class of antidepressants. 
My research was designed to investigate three possible alternate 
mechanisms of action for the tricyclics, which might correlate bett91' 
with the requirement for chronic administration. 
v. 
OUr results demonstrated that tricyclic antidepressant drugs, 
when administered chronically, do not alttr monoamine oxidase activity 
in vivo in any of the three brain regions we examined (corpus striatua, 
forebrain, and hypothalamus). Similarly, we were not able to identify 
a noradrengeric relationship other than those that were both toxic and 
lethal when thyroid hormone was administered with the tricyclic anti-
depressant drug Protriptyline. We did, however, observe that in the 
hyperthyroid condition norepinephrine turnover is decreased in hypo-
thalamus when compared to control animals. 
The results we obtained from chronic protriptyline administration 
and its effects on norepinephrine levels and turnover, as well as the 
results we obtained when yohimbine was employed are enlightening. 
Chronic protriptyline administration produced decreased norepinephrine 
levels in hypothala11Us, and decreased norepinephrine turnover, when 
compared to saline administered controls. The alpha-receptor antagonist 
(yohimbine} produced only minor effects on norepinephrine levels and 
turnover when experimental animals were pretreated chronically (18 days) 
with protriptyline. 
These results suggest an adaptive response (hypo-sensitivity) of 
the presynaptic alpha-receptor (autoreceptor), and this phenomena 
also occurs at the post-synaptic alpha-receptor. These results, 
suggesting receptor adaptation, indicated the existence of another 
mechanism of action for the tricyclic antidepressants. 
vi. 
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C H A P T E R I. 
C H A P T E R I. 
INTRODUCTION: 
Durln1 the past 25 years many facts have been documented regardlq 
the anatomical and biochmical phenomena which are correlated with mood.. 
This eviderx:e has implicated the involv .. ent of brain neural. systema 
which employ norepinephrlne (NE) aa their neurotransaitter (Glowinski 
and Iversen, 1966; Kobayashi,.!!_!!_., 1974; Ross and Reis, 1974; and 
Malbon, 1979). From these studies and theories the "catecholamine 
hypothesis for affective disorders" has been derived (Bunney and Davis, 
1965; Schildkraut and Kety, 1967; Segal, !!_al., 1974; Baldessarini, 
1975; Leonard, 1975; de la Fuente, 1979; and Stern, _!!al., 1980). 
This theory states that elevated mood is associated with an 
increased interaction of brain NE with its respective receptors; whereas, 
a depressed mood. is associated with a decreased interaction between NE 
and respective receptors. In addition, it is also proposed that some, 
if not all, depressions are associated with an absolute or relative 
deficierx:y of catecholamines, in particular NE, at the functionally 
important ad.renergic receptor sites in the brain (McClure, 1971; McClure, 
1973; and Barchas, !.!. al., 1978). Srudies in man have also shown that 
drugs which cause depletion and inactivation of NE centrally produce 
sedation and/or depression, while drugs which increase or potentiate 
brain NE levels are associated with behavioral stimulation or excitation 
and generally exert an antidepressant effect. 
An additional building block for this theory lies in the fact 
that tricyclic antidepressants (TCA's), which normalize a depressed mood, 
l 
2 
block th• active reuptake of NE after its release frOll the presynaptic 
n·erTe t ... inala (Rossi, 1976; Kant and Meyerhoff, 1977; and Sulser, et 
~·, 1978). The reuptake process is believed to be the primary means 
for t8l'11inating the post-synaptic action of NE, and the tricyclics are 
able to increase the time for released NE to interact with respective 
target cell receptors (Wurtman, 1965; and Iversen, 1973). 
Other evidence (Alpers and Himwich, 1972: Frazer, et al., 1978; 
and de Montigny and Aghajanian, 1978) suggests that the ability of the 
tricyclics to block NE reuptake, though the primary mechanism of action, 
may not be their only mechanism of action. Blockade of NE reuptake 
can be demonstrated after a single injection of a TCA drug (Callingham, 
1967; Tod.rick and Tait, 1969; Schildkraut, et al., 1970; and Oswald, et 
al., 1972). Paradoxically, tricyclics do not exert a clinically observ-
able antidepressant effect unless given chronically for two to three 
weeks. Therefore, blockade of the reuptake mechaniS11 cannot be re-
conciled with the time course (lag-time) for the chronic clinical 
efficacy of these drugs. 
As a further building block adding support to the idea that 
tricyclics act by another mechanisa is the observation that TCA drugs 
inhibit monoaaine oxidase (MAO) activity in vitro (Gabay and Valcourt, 
1968; Halaris, et !!_., 1973; Roth and Gillis, 19744; and Roth and Gillis, 
197~b). MAO is a mitochondrial bound intracellular NE degrading enzyme 
(Johnston, 1968; Schnaitman and Greenawalt, 1968; and Greenawalt, 1972). 
If specific enzymatic parameters regarding NE degradation diff9l' between 
normal individuals and patients prone to endogeneoua depression, then 
3 
tricyclica may exert their antidepressant influence• by altering or 
returnin1 to normal certain enzyme imbalances. These imbalances may 
only be changed during long-term tricyclic treat'llent, Le. MAO 
inhibition (Nies, et al., 1971; Youdia am Holzhauer, 1976; and Sulli-
van, et al., 1977). 
Since NE availability at post-synaptic receptor sites is one of 
the fundamental correlates for mood changes (depression or anxiety) it 
has also been suggested that cellular NE levels rna.y decrease in 
individuals prone to endogeneous depression, and chronic administration 
of tricyclics reduce or prevent these changes (Schildkraut, et al., 
1970; Schildkraut, et al., 1971; and Leonard. and Kafoe, 1976). 
Contrary to these findings however, Neff and Costa (1967) and Alpers 
and Himwich (1972) have reported that chronic TCA treatment with imipra-
mine or protriptyline did not induce changes in cellular NE levels in 
rat brain. 
The effect of chronic tricyclic administration on NE turnover has 
also been suggested as a possible mechanism or parameter which may be 
altered by chronically administered tricyclics ( Schildkraut, et al., 
1970; Schildkraut, et al., 1971; and Leonard and Kafoe, 1976); but 
this hypothesis is not supported by other studies (Neff and Costa, 
1967; and Alpers and Himwich, 1972). 
Another hypothesis this research investigated dealt with the 
effects and interrelationships between thyroid hormone administration 
and TCA drugs; and their individual and/or combined abilities to 
alleviate several depressive synaptoms observed in clinically depressed 
patients. Studies by Prange, et!!_., (1970), Wheatley, (1972) and 
Slushc-, (1975), have reported confirming results that both patient 
mood and behavior improved when thyroid hormone was administered in 
conjunction with tricyclics, but the biochemical reasons for this 
improvement in mental health remains unresolved. 
It has been documented that dysfunction of the thyroid gland 
has long been associated with mental illness (Gibson, 1962; Prange, et 
al., 1969; Breese, et !!_., 1974; Slusher, 1975; Singhal and Rastogi, 
1978; and Bain and Walfish, 1978). Consequently, symptoma of depression 
are frequently associated with hypothyroidism; whereas, anxiety, fatigue 
and irritability are associated with hyperthyroidism. It may be proposed 
that endogeneous affective disorders are linked specifically to overall 
thyroid status. This hypothesis has been suggested and states that in 
hyperthyroidism there is increased receptor sensitivity (Emlen, et al., 
1972; Engstran, et al., 1974; Engstra1, et al., 1975; and Strombom, et al., 
1977), which induces, through canpensatory mechanisms, a reduced 
neuronal activity and decreased NE turnover, both of which result from a 
negative feedback mechanism (Strombom, !! al., 1977; Oppenheimer, 1979; 
and Sterling, 1979). Conversely, the opposite would occur in hypo-
thyroidism. Therefore, concurrent administration of thyroid analogs with 
tricyclics should hasten the biochemical mechanisms of action elicited 
by chronic tricyclic treatment. This would yield a shorter time interval 
for clinical efficacy for these drugs and would result in an elevated 
mood (Earle, 1970; Wilson, et al., 1970; and Wheatley, 1972). 
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This aspect of this research study was designed t_o investigate and 
identify any possible central nervous system (CNS) biochaaical 111echanit111 
which might be altered following both concurrent thyroid hormone and 
tricyclic administration which may accelerate improvement in a depressed 
patient. 
In summary, this study investigated several hypotheses which were 
suggested as alternative mechanisms of action associated with tricyclic 
administration, and possibly resolve the existing controversy ovsr the 
occurrence of a lag-time, between drug administration and clinical 
efficacy. Also, this study was designed to identify the relationship 
between thyroid hormone administration, tricyclics and accelerated 
clinical improv .. ent in depressed patients. 
The several hypotheses this research attempts to test follow: 
(l) that the requirement for chronic treatment with TCA 
drugs before clinical efficacy is observed is related to an action on 
mitochondrial MAO, and that the time course for this effect parallels 
the time course for clinical response. 
(2) that simultaneous administration of thyroid hormone 
potentiates the action of TCA drugs through an effect on MAO activity, 
NE turnover or NE cellular levels • 
(3) that the time course in clinical efficacy of TCA drugs 
parallels the time course for development of presynaptic receptor 
subsensitivity (arxi concommitant changes in neurotransmittezo turnover). 
Investigations into these possible alternative mechanisms of action 
of the tricyclics may shed soma light on clinical TCA drug treatment, 
arxi the clinical efficacy of this class of drugs. These results may aid 
research_.• and clinicians in reconciling the unresolved time-course or 
lag-time associated with these drugs and with their observable clinical 
actions. 
C H A P T E R II. 
C H A P T E R II. 
A. HONOAMINE OXIDASE: A Review of History, Current Research and 
Interrelationships with Depressive Illness. 
6 
The term 'monoamin• oxidase' (MAO) (02 oxido-reductase, deaminat-
ing, E. c. l.4.3.4) is used to designate a group of enzymes catalyzing 
the oxidative deamination of tyramine, tryptamine, serotonin, norepi-
nephrine, dopamine and other monoamines. These enzymes are mainly bound 
to the outer mitochondrial m•brane. They were first identified by 
Hare, (1928) as tyramine oxidases, and were further characterized by 
Blaschko, _!!al. (1937, 1954). Pugh and Quastel (1937) were the first 
researchers to study MAO activity in nerve tissue. MAO activity varies 
greatly in different regions of the brain, with highest activity being 
observed in the hypothalamus and basal ganglia (Collins, et al. , 
1970; Youdi11, l973A, Youdim, 1973B; and Hazama, !!_al., 1976). The 
first studies on the intracellular localization of MAO were performed 
by Hawkins (1952) and Blaschko (1957). These independent investigators 
observed that in adult rat liver homogenates 70-80\ of the total MAO 
activity is found in the microsomal fraction of the subcellular 
fractionation preparation. 
Evidence that MAO is localized. in the outer mitochondrial membrane 
was first observed and reported by Schnaitman, !!. al. (1967), with 
additional support added by de Champlain, !!_al. (1969). This close 
association between MAO and the mitochondrial membrane has complicated 
the purification of the enzyme, and the study of its pure chemical nature 
7 
and charact .. lstic enzymatic paraaet_.s can only be examined using 
subcellular mitochondrial preparations employing unsolublllzed partially 
purified enzyme preparations. 
There is substantial evidence available which states that MAO 
exists in more than one form (Gorkin, 1966; Sandler and Youdi11, 1972; 
Houslay and Tipton, 1973; Neff and Yang, 1974; Neff, et al., 1974; and 
Youdim and Collins, 1975). Multiple forms of human brain mitochondrial 
MAO were first described by Collins, et al. (1970). The presence of 
different forms of MAO in tissue hccaogenates, mitochondrial preparatlona 
and in carefully prepared outer mitochondrial membrane preparations has 
been supported by the discovery of substrate selective inhibitors of 
MAO. The two drugs employed for the specific characterization of MAO 
forms were clorgyline and deprenil (Johnston, 1968; Knoll and Magyar, 
1972; Houslay and Tipton, 1974; Neff, et al., 1974; and Bakhle and Youdim, 
1975). 
Johnston, (1968), .proposed that clorgyline allows the investigator 
to distinguish with in vitro and in vivo rnet~odologies between two 
forms of brain MAO; termed Type A and Type B enzyme. Type A enzyme is 
.thus very sensitive to clorgyllne and preferentially deaminates 5-
hydroxytryptamine and norepinephrlne. Type B enzyme is specifically 
inhibited by deprenil and ls relatively insensitive to clorgyllne (Knoll 
and Magyar, 1972). For the Type B form of MAO preferential substrates 
include benzylamlne and phenylethylamine (Houslay and Tipton, 1974). 
Dopamine, tyramine and tryptamine are substrates for both enzyme 
forms (Full_., 1972; Squires, 1972; Yang and Neff, 1973; and Neff and 
Yang, 1974). 
8 
There is also significant evidence suggesting that intraneuronal 
MAO plays an important role in regulating the functionally active poola 
of NE in the nerTe cell cytoplasa in the neurons of the CNS (Kopin, 
1964; Bloom and Giarman, 1969; Green and Grahame-Smith, 1975; Youdim, 
l975a; Youdim, 1975b; and Youdim, l97Sc). The exact mechanism by 
which regulation for these homeostatic processes is accomplished by MAO 
has not yet been resolved. Intraneuronal MAO may metabolize neuro-
transmitter monoamines before and/or after reuptake into the presynaptic 
nerve ending, following stimulated release. 
This degradative process appears to depend solely upon the 
activity of the MAO enzyme present in the nerve terminals and post-
synaptic structures. The reuptake process also appears to be governed 
or regulated by the relative concentrations of free intra- and extra-
neuronal NE. MAO is apparently essential for keeping cytoplasmic NE 
in the neuron low, and within a specific steady-state equilibrium. 
Under conditions when MAO activity is decreased (HAO-inhibitor adminis-
tration) the concentration of total cytoplasmic NE rises. It has also 
been suggested (Bloom, 1963; Eiduson, !!_al., 1964; Kordon and Glowinski, 
1970; and Gripois, 1975) that NE which is present in the presynaptic 
neuron cytoplasm may react with the MAO enzyme in the cytoplasm and 
cause a change in the steric conformational structure of the MAO 
enzyme. This may or may not be reversible. This staric conformational 
9 
change in MAO results in an activity cha.nge (i.e. increasing or 
decreasing MAO activity in the cytoplasm) and has been further documented 
by Iversen, et al. ( 1975). This change in enzyme structure, which haa 
been substrate induced, may alter the specific activity of MAO toward a 
specific substrate, and paradoxically not change the affinity for this 
substrate (NE). 
Possibilities for these conformational changes in the enzyme 
molecule could occur by "folding" of MAO chains, since the enzyme 
exists as a monomer, dimer and tetramer (Collins and Southgate, 1970; 
Gerkin, 1972; Southgate, 1972; and Yasunobu and Oi, 1972). Each MAO 
chain has a molecular weight of 75,000. Folding of these chains could 
result in reducing the activity of the enzyme (i.e., less accessibility 
of the substrate (NE) to the enzyme's active sites); or folding may 
initiate a self-catalytic process, or enzyme inactivation process which 
may or may not be reversible. Similarly, it has been suggested 
(Eiduson, et al., 1964), that the MAO degrading mechanis11 consists of 
a three-point attachment to the enzyme surface by the catecholamine, 
which very likely involves the amine, one alpha hydrogen, and either the 
other alpha hydrogen or the beta-methylene, once again substantiating the 
complexity of this structure-activity relationship, .and the possible 
steric variations for inactivity that are available. 
It appears there is a self-regulatory mechaniSlll in the nerve cell 
cytoplasa which can increase intraneuronal NE concentrations or decrease 
NE levels. This process is dependent upon signals which are increased 
or decreased, sequential to neural firing rates. 
lO 
In moat theories of brain dysfunction and function, HAO is of 
significant importance. Any change in the HAO activity usually alters 
th• function of a specific CNS neurotransmitter, and in particular NE. 
A physiological role far HAO baa been implicated in many processes: 
affective disorders, agressive behavior, psychosanatic stimulation, 
severe mood and behavioral changes leading to crimes of violence and 
suicide (Ashcroft, et al., 1966; Shaw, et al., 1967; Bourne, et al., 
1968; and Nies, et al., 1971); drug induced seizures, sleep, environ-
mental stress, hallicugen action (Glowinski, 1966; Garver, et al., 
1975; Schildkraut, et al., 1976; Becker and Shaskan, 1977; Orsulak, 
!! al., 1978; Baron, et al., 1980; Meltzer, et al., 1980); regulatory 
effects of adrenocortical steroids and of ovarian hormones, temperature 
regulation and eating (Glick and Greenberg, 1958; Avakian and Calling-
ha11, 1968; Southgate, et al., 1968; Carpenter and Bunney, 1971; 
Callingham and Della Corte, 1971; Holzbauer and Youdim, 1973; Ruhmann-
Wennhold aod Nelson, 1973; Garver, et al., 1975; Otten and Thoenen, 
1976; and Rastogi and Singhal, 1978). 
Since MAO exists in multiple forms (Johnston, 1968; Youdim, 1973; 
Houslay and Tipton, 1976; Green, !!_al., 1977; Jain, 1977; Student and 
Edwards, 1977; Trepel, et al., 1977; and Fowler and Callingham, 1978), 
and because it has a central role in the degradation of biogenic amines, 
the therapeutic benefit of drugs which inhibit this enzyme in clinical 
treatments deem it imperative that MAO be examined following both acute 
and chronic tricyclic administration. 
ll 
Since the possibility exists that alterations in the metabolism 
of central ta0noaminea cause several mental disorders, many investigatara 
have studied HAO activities in the CNS (Leonard, 1975; Youdim and 
Holzbauer, 1976; Ananth and Luchins, 1977; and Barchas, et al., 1978). 
Ashcroft and Sharman (1960) ware the first researchers to measure the 
metabolites of biogenic amines in the cerebral spinal fluid (CSF) of 
mentally ill patients. In certain types of endogeneous depression low 
CSF concentrations of 5-Hydroxy Indole Acetic Acid (5-HIAA) ware 
observed (Daneker, et al., 1966; van Praag, et al., 1970; and Sjostrcm, 
1973). These findings also agree with the lower 5-hydroxytryptamine and 
5-HIAA concentrations found in post-mortem brains of patients with 
depressive illness who committed suicide (Shaw, !!_al., 1967; and Bourne, 
et al., 1968). 
Further supporot for a possible link between MAO and mental illness 
is documented by the beneficial effects achieved with drugs which in-
hibit MAO (Shaw and Hewland, 1973; Davidson, 1974; Neff, et al., 
1974; Ananth and Lucins, 1977; and Campbell, et al., 1979). Since 
alterations in monoamine metabolism can occur during their degradation, 
variations in the function of MAO could ultimately result in a dys-
function of the neural pathways in which the respective monoamine (NE) 
plays a role as a specific transmitter substance. It is therefore 
important that the influence of tricyclics on HAO, when administered 
both acutely and chronically be examined (Roth and Gillis, 1975; Spiker 
and Pugh, 1976; Gabay and Achee, 1977; Honecker and Hill, 1977; Ponto, 
!!_al., 1977; Roth, 1978; and Ach" and Gabay, 1978). These studies are 
-. 
imperative if we are to understand the interrelationship between tri-
cyclics and delayed clinical efficacy. 
B. PROCEDURE AND METHODS 
l. General experimental procedures. 
Male albino rat (Charles River Laboratories, C.D. Strain, 
COBS) weighing 250-400 grams were used for the determination of HAO 
activity levels, NE pool size levels and NE turnover studies, as well 
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as for all studies involving thyroid hormone interrelationships. All 
animals were housed in the animal care facility at Rhode Island Hospital 
and were maintained at the ambient temperature of 20-22° c. These 
animals were given Purina Rat Chow and watal' !! libitwn and were subjected 
to a 14-hour lighting cycle ( 0500-1900 hour ·, ; • 
2. Drugs employed. 
Radioactive substrates for monoamine oxidase included c14-
tryptamine bisuccinate and cl4-5-hydroxytryptamine. These chemical were 
purchased from New England Nuclear, Waltham, Mass. and are listed under 
the following catalogue numbers: NEC 259, tryptamine; NEC 225, 5-
hydroxytryptamine. 
The tricyclic antidepressant drug employed in these studies 
was protriptyline (Vivactil) manufactured by Merck Sharp & Dohme, 
Pennsylvania. Protriptyline was chosen as our experimental drug since 
it is a secondary amine tricyclic which preferentially blocks reuptake 
of the catecholamine NE (Ross and Reny!, l975a; Ross and Renyi, l975a; 
Ros• and Reny!, l975b). Desipramine, desmethylchlorimipramine and 
nortriptyline are other similar secondary tricyclics. In contrast, 
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imipramine, amitriptyline and doxepin are classified as tertiary 
amines, and preferentially block th• reuptake of serotonin (Rossi, 1976). 
3. Assay for monoamine oxidase. 
MAO activity was measured by the method of Wurtman and Axelrod 
(l 963). Rats were decapitated and brain tissues were surgically excised. 
The surgically removed ~issues were weighed by flotation in 0.5 M 
potassium phosphate buffer (pH 7.4), 15 ml total volume. Tissues were 
then homogenized by a polytron cell disrupter (Modal PT-10/20, with PT-
10, ST generator, Brinkman, Switzerland) for two minutes at high speed 
(dial setting 10). All preparations were kept in an ice bath during cell 
disruption. Following cell disruption, 100 ul aliquots of each tissue 
sample was placed in assay tubes and reacted with labelled tryptamine 
bissuccinate or 5-hydroxytryptamine (New England Nuclear, NEC 259, and 
NEC 225), which were used as the substrates for the MAO enzyme. 
The total assay volume was 1.2 ml (0.5 ml potassium buffer, pH 
7.4; 0.5 ml distilled water; O.l ml tissue homogenate; and 0.1 ml 
substrate solution). Assay tubes were incubated for 20 minutes in a 
shaker water bath at 37° c. At the end of the incubation period, the 
reaction was quenched with 0.2 ml of 2.0 N HCL. This caused denaturing 
of MAO and prevented further substrate degradation (deamination). The 
deaminated radioactive products, 5-HIAA and Indole Acetic Acid (IAA), 
were then extracted by vigorous shaking with 6.0 ml of a toluene/ 
ether solution (l:l). This procedure is a modification of the original 
Wurtman and Axelrod (1963) method, and allows a more efficient 
extraction of radioactive products ( 5-HIAA and IAA). Efficiency was 
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increased frcm 62+ 2\ to 82+ 4\ and was used in all subsequent MAO 
determinations (Kaiser, 1975A). Following a 10 minute centrifugation, 
(IEC International Centrifuge, Model PR-2) of this mixture (2000 rpm, 
280 x g), a 4.0 ml aliquot of the organic phase was transferred to a 
liquid scintillation counting vial containing 10.0 ml phosphor [0.4 
gram p-Bis-(2-5-phenyloxazolyl-benzene)] (POPOP), and 4.0 grams 2,5-
diphenyloxazole (PPO) per liter of toluene (Bray, 1960). These samples 
were then counted in a liquid scintillation counter (spectrophotometer) 
(Searle Analytical, Mark III) for 10 minutes. A small amount of 14c-
tryptamine or 14c-5-hydroxytryptamine (less than 0.3\) (Kaiser, 19758) 
was extracted by this procedure, but it creates a negligible error in 
the extracted radioactive samples. 
4. DNA methociology. 
Homogenized tissue aliquots of O.l ml. were taken from the cell 
preparations previously described (assay for MAO), placed in 15 .o ml 
graduated conical centrifuge tubes, and frozen until assayed. A 
standard DNA stock solution was prepared containing 200 mg of deoxyri-
bonucleic acid sodium salt (highly polymerized, grade A, Cal-Biochem, 
La Jolla, CA.) per 100 ml of 1.0 N arrnoniwn hydroxide (NH40H). This 
solution was stored at 4° c. 
Standards of l.O, 2.0, 4.0, a.o and 12.0 ug DNA per sample were 
run with each assay in order to check their reproducibility and pre-
cision. All samples were then assayed by the method of Kissane and 
Robins (1958), which has been slightly modified to allow the use of 
larger tissue samples (Wunschel, personal co1DJ1unication). Modifications 
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involved the use of proportionately larger volWRea of reagents for the 
extraction procedures. All samples were assayed in triplicate and av-
eraged. 
The calculations involved in determining the DNA standard Curve, 
the linear regression analysis to obtain the regression coefficient, 
and a graphical representation of the data can be found in the Appendix 
sect ion, Figure 
5. Scintillation counter efficiency adjustment and DNA calculations. 
The calculations involved far the conversion of counts per 
minute (CPM) to nanomoles of IAA or 5-HIAA formed per hour per ug DNA 
follow: 
I. For Efficiency Adjustment: 
Disintegrations per minute (DPH) = counts per minute (CPH) 
counting efficiency of 
counter 
II. Conversion Equation (To convert DPH's to nanomoles of 
(5-HIAA or IAA formed per hour per ug DNA) 
DPM x dilution factor x 
counts of radioactive 
material used ~total 
substrated added to 
samples) 
nanomoles of radioactive x 3* x 3•• = 
product formed ~ r 
nanomoles of IAA or 5-HIAA ~ ug of DNA per 100 ul sample 
formed per hour per gram 
= nanomoles of product formed per hour per gram per ug DNA. 
*This ratio refers to the volume of organic solution 
extracted in the separation procedure. 
**This ratio refer:'s to a reaction incubation time adjustment. 
. , 
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C. RESULTS 
Initial. experiments involving the determination of MAO activity 
levels in brain tissue were concerned with e><.a11ining the enzymatic 
kinetic parameters of the enzyme. Classical velocity (V) versus time 
(T), and velocity (V) versus enzyme (E) concentration experiments were 
performed using homogenized tissue preparations from the three brain 
regions being examined (corpus stria tum, forebrain and hypothalamus). 
From these studies it was determined that a twenty minute incubation 
time, and a 100 ul aliquot of each homogenized tissue preparation would_ 
produce linearity, and neither time nor enzyme concentration would be 
limiting variables in future expar'iments. 
Following these studies and employing both a twenty minute incubation 
time and the 100 ul aliquot of the homogenized brain tissue preparations, 
further experiments were conducted to determine both Km and Vmax values 
for the MAO enzyme in these three brain regions (see appendix section 
Figures 1-4; Tables 14-26. 
After completing the enzymatic kinetic parameter studies, MAO 
activity levels were measured in the same three regions of rat brain in 
control animals. From these results it is apparent that in these brain 
regions there exists about ~ times more B-form MAO than A-form MAO, 
since cl4-serotonin is selective for only the A-fora of MAO, whereas 
cl~-tryptamine is deaminated by both the A and B forms of MAO. These 
values are reported in Table 1. When cl~-tryptamine was employed as 
substrate for MAO, the total nmoles of product fornied/hr/ug DNA is 
significantly greater (p~0.001) than when cl~-serotonin was used as the 
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MAO enzyme substrate. Also, it is apparent that the forebrain prepu-a-
tion ha• significantly more MAO activity (p~O.Ol) than the other two 
brain regions being examined, regardless of whether cl4-tryptamine or 
cl4-serotonin waa employed as the MAO substrate. 
TISSUE 
TABLE l Monoamine oxidase activity levels in three 
regions of rat brain under control conditions. 
CH-serotonin cl4-tryptamin• 
Corpus Striatwa 0.4462 + 0.032*(N=8) 2.2638 + 0.161 (N=l2) 
Forebrain 0,5926 + 0.032 (N=6) 3.1692 + 0.139 (N:8) 
Hypothalamus 0.3623 + 0.015 (N=5) 2.1469 + 0.061 (N=S) 
*Values represent the Mean + S.E.H. and are reported as 
nanomoles IAA or 5-HIAA formed/hr/ug DNA 
Next, an initial set of experiments was undertaken to examine the 
effect of protriptyline on MAO activity in vitro (appendix section, 
Figures 5 and 6). Corpus striatum, forebrain and hypothalamus wEIE'e 
dissected out of whole brain and homogenized in phosphate buffer 
(pH 7.4). Aliquots (100 ul) of these homogenized tissue preparations 
were then placed in reaction tubes and preincubated with varying molar 
concentrations of protriptyline (10-ll to lo-3 ~) for thirty minutes at 
20° C, prior to addition of labelled substrate as described in the 
Methods Section. 
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The results fro• these exp.r!ments report that when the concen-
tration of protriptyline in the preincubation media approaches l0-6 M, 
MAO enzyme activity in the corpus striatum is inhibited when either 
c14-tryptamine or c14-serotonin are used as substrate. Similar results 
were observed in both forebrain and hypothalamus. We interpret these 
results to be a non-specific inhibitory effect. Numerical values and 
graphical illustrations are reported in the appendix section (Figures 
5 and 6; Tables 27 and 28). 
The next area this research investigated involved measuring 
the in vivo effects of protriptyline on MAO activity. Protriptyline was 
administered to experimental animals (male albino rats, Charles River, 
C.D. Strain) acutely (one daily injection), subchronically (3 or 6 
daily injections) and chronically (18 daily injections}. A dose of 
10 mg/kg/day protriptyline hydrochlcride dissolved in physiological 
saline was administered for this regiment of injections. This dose of 
protriptyline was selected since it appears extensively in the literature 
(Schildraut, et al., 1971; Leonard and Kafoe, 1976; Rossi, 1976). 
This dose of protriptyline is between 10 and 20 times the dose used in 
treating clinical depression (Long, 1977). 
The results of these experiments are presented in the appendix 
sect ion (Tables 3, 4, 5 and 6} • Our observations from these stud iea 
indicated that .!E_ vivo protriptyline administration had no consistent 
effect upon MAO activity in the brain tissues we examined regardless of 
length of administration (l, 3, 6 or 18 consecutive injections) and 
regardless of whether MAO activity was examined l, 3, 6, 12 or 24 hours 
after the last ~rug administration. 
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D. DISCUSSION 
The activity of monoamine oxidase, one of the degrading enzymes 
in the metabolism of the neurotransmitter NE, has been measured under 
various experimental procedures in several regions of rat brain. This 
area of investigation was pursued, since the mechanism of action of the 
tricyclics remains controversial. Specific actions of the tricyclics 
on MAO activity may explain why chronic treatment is required to produce 
clinical efficacy. 
We began our studies by initially developing and optimizing both 
our methodology and technique for isolating and quantitatively measuring 
tissue MAO. The numerical data we obtained for our enzymic kinetic 
parameters is supported by other investigators, and this adds support 
and validity to our procedures. 
When examining the in vitro effects of protriptyline preincubation 
on MAO activity, we observed a decrease in enzyme activity at concen-
trations of lo-6 .!!_and higher. Similar results for the tricyclics 
(i.e. MAO inhibition) have been reported by other investigators (Gabay 
and Valcourt, 1968A; Halaris, !!_al., 1973; Roth and Gillis, 1974A; 
Roth and Gillis, 1974B; Roth and Gillis, 1975; Roth, 1977). 
Examining the effects of acute (one daily injection), subchronic 
(three or six daily injections) or chronic (eighteen daily injections) 
protriptyline administration in vivo on MAO activity, we found no 
consistently significant effect of protriptyline on MAO activity in 
the brain regions we examined. 
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Having extensively researched the first hypothesis of this study. 
and concluding that no specific in vivo effect for protriptyline on MAO 
activity could be substantiated, we proceeded to test our second 
hypothesis, "that thyroid hormone interacts with the tricyclics and 
may potentiate their effect on MAO activity, NE turnover, and on 
cellular NE levels." 
C H A P T E R III 
C HA P T E R III. 
A. THE THYROID HORMONES: Thyroid status and its interrelationship 
with monoa.mine oxidase, norepinephrine biosynthesis and the tricyclic 
antidepressant drugs. 
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The mechanism of action of the thyroid hormones (T3 and T4) is of 
considerable interest because of the amazing diversity of their effects 
(Fleischmann, 1947; Fischer, et al., 1968; Prange, !!. al., 1971; Breese, 
et al. , l 974; Strombom, et al" 1977; Singhal and Rastogi, l 978 ) • 
These hormones exert profound effects on many enzymes and on al.most all 
organ systems. Th~ also play an important role in the complex bio-
logical processes involved in growth and cell differentiation (Oppen-
heimer, 1978). These hormones are thought to cause their actions by 
modulating or regulating the actions of other endogenous hormones or 
enzymes (Barchas, et al., 1978). This is accanplished by influencing 
thyroid hormone receptors associated with the nuclear chromatin (Ster-
ling, 1979); and by al taring mitochondrial function (Sterling, et al., 
1978). The concept of an intracellular, nuclear receptor for thyroid 
hormone is based on earlier receptor models, which have been theorized 
for the action of steroid hormone action on respective target cells. 
In these models hormone action occurs via nuclear transcription (Samuels 
and Tsai, 1973; De Groot and Stausser, 1974; Samuels, et al., 1974; 
De Groot and Torresani, 1975; Mac Leod and Baxter, 1976; Chan and 
O'Malley, 1976). Other researchers (Gardner, 1975; Oppenheimer, 1975; 
Kurtz, et al., 1976; Surks and Oppenheimer, 1977), suggest that the 
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hor110ne penetrates the plasma aaabrane and is bound by a specific 
cytosol receptor. This hormone-receptor complex enters the nucleus, 
and increased transcription of a genetic message for increased mRNA 
occurs. This in turn results in mRNA directing increased synthesis of 
specific nuclear proteins. 
Ample evidence is available to support the view that an associa-
tion exists between mental disturbances and altered levels of hormones 
such as adrenal corticoids, thyroid hormones, androgens and the estro-
gens (Rubin and Mandell, 1966; Mandell and Mandell, 1967; Dewhurst, et 
al., 1969; Glass, !! al., 1971; Wheatley, 1972). Only recently 
neuroendocrinologists have become interested in studying the effects 
of hormones on the functioning of the brain. Psychiatrists, however, 
have felt for many years that the solution to several etiological 
problems in psychiatry would becane manifest only after a better 
understanding of neuroendocrinological mechanisms became apparent, and 
in particular those involving thyroid hormone mechanisms (Singhal and 
Rastogi, 1978). 
Since the earliest descriptions of both hyperthyroidism and 
hypothyroidism, it has been suggested that certain psychiatric disorders 
may be manifestations of thyroid dysfunction. The clinically observable 
symptoms of thyroid dysfunction are sometimes of such severity that 
they bring the patient to the attention of the psychiatrist, and 
occasionally demand psychiatric hospitalization. 
In clinical studies conducted (Jefferys, 1972; Thomson, et al., 
1972; Mc I.arty, !!al., 1978; Nusynowitz and Young, 1979; Cohen and 
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Swigar, 1979), the prevalence of thyroid dysfunction in a psychiatric 
population (1320 patients) was 1.2\ for males and 2.0\ for females. It 
is doubtful whether these figures are significantly different from the 
prevalence of thyroid dysfunction in the general population (Whybrow, 
~al., 1969; Henschke and Pain, 1977; Tunbridge, !!_al., 1977). This 
suggests that the importance of thyroid disease and mental disturbances 
may not be of important clinical significance. Therefore, the value of 
thyroid function testing in psychiatric patients is still unclear. 
There are two criteria however, which must be discussed. First, thyroid 
dysfunction, (hypothyroidism or hyperthyroidism) may manifest itself as 
a psychiatric illness, and consequently some of the signs and symptans 
of mental derangement mimic those observed in thyroid dysfunction 
(Singhal and Rastogi, 1978; de la Fuente, 1979). Thus, the diagnosis 
of these conditions on overt clinical parameters is sometimes very 
difficult. The occurrence or prevalence of thyroid dysfunction in a 
psychiatrically ill population is uncertain, and has been reported to 
be higher than the gen9:1"al population (Nicholson, !!_al., 1976; Wein-
berg and Katzell, 1977). It has also been reported to be the same as 
the general population (Bursten, 1961; Gibson, 1962; Clower, !!al., 
1969). It is also clear that the stress caused by various types of acute 
and chronic organic illness profoundly affect thyroid function tests 
(Johansson, et al., 1972; Mason, et al., 1973; Mason, 1975}. Although 
psychiatric illness may produce similar alterations in thyroid status, 
the magnitude, duration, and frequency of these thyroid changes are un-
clear and require examination. 
24 
It was our intent to study the interrelationships between MAO 
activity in various brain regions following both in vitro pre-incubation 
with thyroid hormone {T3 and T4 ) and also following in vivo subcutaneous 
injection of thyroid hormone far varying time periods. Also, we studied 
the effects of thyroidectomy on MAO activity. The thyroid hormones are 
known to exert important influences on the central nervous system {CNS) 
{Fleischmann, 1947; Gibson, 1962; Harrison, 1964; Bain and Walfish, 
1978; Oppenheimer, 1979; and Sterling, 1979), ani in particular on both 
peripheral and CNS MAO activity {Novick, 1961; Fisher, et al., 1968; 
Breese, et al., 1974; Callingham and Lyles, 1974; Moonat, et al., 
1975; Lyles and Callingham, 1976; Asaad and Clarke, 1978). It has been 
suggested by Novick, (1961) and Youdim and Holzbauer, (1976), that the 
thyroid hormones modify MAO activity, but the specific mechanisms by 
which these changes occur have not been resolved. There exists the 
possibility of modulating the biogenesis of mitochondria. This theory 
has been advanced by other researchers . (Novick, 1961; Youdi.m ani Holz-
hauer, 1976). Also, ·it has been suggested that the thyroid hormones 
can increase the synthesis of MAO itself (Fischer, et al., 1968). 
This theory has been docwnentad for heart tissue (Coville and Telford, 
1970; Lyles ani Callingham, 1976). Al.so, it has been suggested that 
the thyroid hormones activate an inactive cytoplasmic MAO in brain 
tissue (Asaad and Clarke, 1976). Conversely, however, rat liver MAO 
activity was decreased following thyroid hormone administration (Moonat, 
et al., 197 5). Thus, any apparent thyroid hormone induced influences 
on MAO activity still remain unclear, and also tissue specific. 
Similarly, emotional or mental stress may also be related to possible 
HAO-thyroid relationships, and these relationships should be investi-
gated. 
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With regard to norepinephrine levels and norepinephrine turnover 
following either T3 or T4 administration, once again controversies 
exist. Engstrom !!_al., (1974, 1975) as well as Schwark and Keesey 
(197 5) have stated that T4 pretreatment has no significant effect on 
brain concentrations of NE, dopamine or serotonin. However, Engstran, 
(1974), Strombom et al., (1977) and Jacoby (1975) have reported 
increased turnover of brain catecholamines following T4 pretreatment. 
Also, Kennedy et al., (1977) reported increased NE turnover in brown 
adipose tissue (BAT) pads of the rat with statistically significant 
increases in NE levels in this tissue with T4 treatment. Contradictory 
to these studies however, Prange et al., (1970), has reported that 
thyroxine pretreatment caused a decrease in NE turnover and levels in 
the rat in both brain and heart tissue. Lastly, studies by Rastogi and 
Singhal (l974a, l974b) have reported an increase in NE levels in brain 
and total animal body weight when T3 was administered. 
Since this controversy exists, regarding the effects of T3 and 
T4 administration on NE levels and turnover, it was imperative to 
include the effects of the thyroid hormones on these NE parameters in 
this study. 
Also, since a similarity exists between the clinical manifestations 
of depression and those of hypothyroidism, the effects of thyroidectomy 
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were investigated in relation to NE levels and turnover. Evidence from 
many clinical and animal studies indicate that a number of metabolic 
ar¥i psychic disturbances are common to both thyroid deficiency ani 
affective illness (Oppenheimer, 1979; Sterling, 1979). 
Biochemical studies have demonstrated that both hypothyroidism 
and depression show a diminished response to infused NE (Schneckloth, 
et al., 1953; Prange, et al., 1967). Furthermore, psychological studies 
have suggested that the symptoms of myxedema, a severe form of hypo-
thyroidism, makes an insidious appearance and is generally characterized 
by listlessness, lack of energy, slowness of speech, reduced sensory 
capacity, impairment of memory, social withdrawal and altered sleep 
patterns (F.ayrs, 1960; Kales, !!_al., 1967). Several of these psycho-
logical symptoms are commonly observed in depressed patients; slowness 
of speech, reduced sensory capacity, lack of energy, social withdrawal, 
and altered sleep patterns (Libow and Durrell, 1965; Whybrow, !!._al., 
1969; Davenport and Dorcey, 1972; Davenport,.!!_ al., 1976). 
Even though there appears to be sufficient evidence to implicate 
thyroid dysfunction with associated depression, it is still impossible 
at present to implicate abnormal thyroid function as a result or a 
cause of affective disorders. In order to possibly clarify this 
hypothesis and gain insight into whether or not alterations in neuro-
transmitter mechanisms (i.e. pool size and/or turnover) cause suppressed 
behavior and learning deficiencies, which are viewed in both depressed 
and hypothyroid patients, we felt that !t was imperative to investigate 
NE parameters during hypothyroidism. 
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Effective pharmacological treatments for mental illness have 
existed only during the last 30 years. This period has also witnessed 
a revolution regarding the care of psychiatric patients and has resulted 
in a decrease in the number of patients in both state and county mental 
facilities. This combination of both drug therapy and psychological 
and socioenvironmental treatment is responsible for the vastly improved 
prognosis for patients with mental illness (Barchas, et al., 1977; 
Berger, et al., 1977; Gold and Pottash, 1981; Spiker, 1981). 
Since a high prevalence of mental dysfunction exists, and also a 
concommitant economic loss due to work disability and/or hospitalization, 
as well as the ever present danger of suicide, a persistent as well as 
compelling reason to search for a treatment for depression, that is both 
rapid, safe and convenient becanes necessary. Since treatment with 
thyroid hormones has been shown to enhance the pharmacological actions 
of several of the barbiturates (Conney and Garren, 1961; Prange, et al., 
1966), and also since other clinical studies (Prange, et al., 1970A; 
Earle, 1970; Prange, !!_al., 19708; Wheatley, 1972; Whybrew, et al., 
1972; Slusher, 1975; and Schmidt, 1977) as well as some animal investi-
gation (Prange and Lipton, 1962; Breese, et al., 1974) have documented 
an increase in drug efficacy, it has been theorized that the thyroid 
hormones may accelerate the antidepressant actions of the tricyclics or 
these other pharmacological agents (Cavalieri and Pitt-Rivers, 1981). 
Keeping in mind these observations we designed our experimental protocol 
to incorporate both protriptyline and T3 administration. We planned to 
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investigate their possible synergistic interrelationships with regard to 
MAO activity, NE levels and NE turnover in three tissues of the rat brain. 
The occurrence of psychiatric symptoms in patients suffering frail 
hypothyroidism is well established (Asher, 1979; Rubin and Mandell, 1966; 
Oppenheimer, 1979; Sterling, 1979). Also, the similarity between the 
manifestations of anxiety states and hyperthyroidism is also well 
established (Dewhurst, et al., 1969; Singhal and Rastogi, 1978; Youdim 
and Holzbauer, 1976). Therefore, whether as a cause or an effect, there 
is evidence which implicates thyroid dysfunction with psychiatric illness. 
Since this strong implication exists, between thyroid status and 
mental illness, it becomes more critical that effective, fast-acting 
pharmacological treatments for mental illness become available. These 
treatments will become available only after sufficient animal research 
has been conducted and only then will there be immense benefits for both 
patients and the general population. 
B. PROCEDURES AND METHODS 
l. General experimental procedures. 
Pharmacological hyperthyroidism was induced by daily subcutaneous 
injection of L-thyroxine (either TJ or T4), 1.0 mg/kg/day, (10 mg/cc in 
normal saline with 2 drops of 1.0 N NaOH) for seven consecutive days 
-
(Barker, et al., 1949; Engstrom, et al., 1975; Kennedy, !_!al., 1977), 
and these animals were then sacrificed on the 8th day by decapitation. 
This dose of thyroxine was sufficient to maintain significantly elevated 
protein bound iodine (PB!) levels (Hammond, 1968; Engstrom, et al., 
1975; Kennedy, et al., 1977). 
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Hypothyroidism was induced by surgical thyroidectomy at 7 weeks 
of age (appraximately 175 grams body weight). a time at which thyroid 
function has stabilized to the adult level (Hammond, 1968; Kennedy, 
et al., 1977; Hamolsky, personal communication). Studies based on 
measurements of protein bound iodine (PBI) levels and basal metabolic 
rate have revealed that significant hypothyroidism does not develop 
in the rat until 7 to 8 weeks post-thyroidectomy (Hammond, 1968; Ken-
nedy, et al.• 1977). Therefore, no measurements other than body weight 
recordings were made until after this time period had passed. 
Also, it is appropriate to note that an age diffat'ence existed 
among the experimental groups being examined, and this partially 
accounts for the observed differences in total body weight. The 
thyroidectomized rats were approximately 18 weeks of age when sacrificed, 
whereas, thyroxine treated animals were 12 weeks of age. In each instance 
corresponding euthyroid animals of equivalent age served as paired 
controls for each experimental group. Also, to adjust for varying total 
body weights and animal age differences, DNA determinations were 
conducted on all brain tissue fractions used in MAO activity level 
measurements. 
2. Assay methodology for norepinephr ine levels and turnover. 
Norepinephrine (NE) in brain tissue was assayed by being 
extracted into o.~ N perchloric acid (PCA) with subsequent purification 
over alumina columns. The NE was oxidized to its trihydroxyindole 
derivative and assayed fluorometrically on a spectrophotofluorometer 
(Aminco-Bowman) by the method of Lund (1950). 
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The method for NE determinations is aa follows: brain tissue 
samples were hcmogenized in 0.4 N PCA (total volume, 10 ml) on a Brink-
man polytron, high speed for 30 seconds. Following hemogenization 
another 25 ml of 0.4 N PCA was added to the homogenate (total voluae -
35 ml). The homogenate was allowed to stand for one hour at 4° C, and 
shaken vigorously every 15 minutes until the hour had elapsed. The 
homogenate was then centrifuged (!EC-International Centrifuge, PR-2, 
2000 rpa, 280 x g) for 20 minutes, and the supernatant was decanted. 
The pH of the supernatant was adjust between 8.3 to 8.5 with o.s _! 
NH40H and 5.0 !!_ NH40H and then poured on alumina columns. The al\D'Dina 
had been prepared by the method of Crout, (1961), (see 3. Alumina 
Preparation), and the NE was adsorbed onto the alumina beads. The NE 
was then eluded off these alumina beads with 0.3 N acetic acid (2.0 
ml). The eluded NE fraction was oxidized with potassium ferricyanide 
(25\) and fluroescence was read on the spectrophotofluoraneter with the 
excitation wavelength at 400 nmeters and emission wavelenght at 510 
nmeters. An external standard with NE as well as an internal standard 
(H3-DL-norepinephrine, New England Nuclear) was simultaneously assayed 
and recovery was 84.4 .!.. 5\ (N=l834 determinations). All values were 
corrected for percentage recovery, (See Appendix Section, Figures 24 
and 25 . ). 
3. Alumina preparation. 
Powdered alumina (Fisher Scientific, chromatographic grade) is 
used for NE adsorption following the acidic activation of this al\.Dina. 
For alumina activation 200-300 grams of neurtral alumina are boiled in 
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one liter of 2 N HCL for 30 minutes in a reflux apparatus. After 
boiling the cloudy supernatant is discarded, and one litm:' of distilled 
water is added to the acidified allDllina while still in the reflux 
apparatus, and stirred briefly. AftC' allowing the alumina to settle,, 
the clear supernatant is decarded. These distilled watm:' washings 
are repeated 12-15 times until the pH of the discarded supernatant 
attains a pH between 4.0-5.o. The alumina is then collected in a large 
suction funnel, and allowed to dry overnight at rOOll temperature 
{20-22°C). The alumina is then heated in an oven at 100° C for 2 hours. 
The alumina is now activated and can be used for NE adsorption. 
~. Alpha-methyl-para-tyrosine procedure. 
Alpha-methyl-para-tyrosine {methyl ester, Sigma Chemical Co.) 
was used to measure NE turnover. This agent canpetitively inhibits 
tyrosine hydroxylase, the rate-limiting enzyme in the synthetic 
pathway for NE biosynthesis. At zero time, 400 mg/kg alpha-methyl-
para-tyrosine {Brodie, et al., 1966) is injected interperitoneally 
(Ip) into both experimental and control animals, and these animals are 
sacrificed by decapitation at varying time intervals after alpha-
methyl-para-tyrosine administration. Depletion rates for all groups of 
animals were determined from 0 to 9 hours after alpha-methyl~para-tyrosine 
injection. 
The validity of this method rests on several assumptions. 
First, NE is assumed to be maintained at a steady state level, existing 
in a single depletable compartment within the nerve ending. In this 
situation only, can efflux rate be said to be equal to synthesis rate. 
32 
Second, that tyrosine hydroxylase ls and remains totally inhibited over 
the entire course of the turnover measurement. Third, that alpha-
methyl-para-tyrosine acts only by blocking NE synthesis, does not intar-
fere with tyrosine uptake (or required cofactors). Also, that the 
mechanisms for release or re-uptake of neurotransmitters are not altered. 
Fourth, that the neuronal pools of both DOPA and dopamine are verry small, 
and thus cannot serve as a reservoir for NE synthesis after tyrosine 
hydroxylase has been inhibited. The fifth, and last criteria, is that 
alpha-methyl-para-tyrosine does not interfer with the experimental 
drug which is being studied. Similarly, the experimental drug cannot 
affect the enzyme inhibiting characteristics of alpha-methyl-para-
tyrosine on tyrosine hydroxylase activity. 
In addition, an alpha-methyl-para-tyrosine dose-response curve 
for tyrosine hydroxylase was performed, resulting in a dose for alpha-
methyl-para-tyrosine which no longer produced an increase in the slope 
of the depletion curve for NE. It was at this dose (400 mg/kg) that 
all synthesis of NE by tyrosine hydroxylase had been inhibited (Figure 
2 ),(Nagatsu, et al., 1964; Spector, et al., 1965; Volicer and Reid, 
-- _ _... 
1969; Costa, 1971; Ostman-Smith, 1979). 
C. RESULTS 
l. Monoamine oxidase activity in three brain regions. 
The effects of prelncubation with tissue homogenate with 
triiodothyronine (T3} on MAO activity in three rat brain regions 
(corpu• striatwa, forebrain and hypothalamus) has been measured using 
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in vitro techniques and employing either cl4_tryptamine or cl4_ 
serotonin aa substrate. In these studies concentrations of T3 of lo-9 M 
and hightr significantly reduced MAO activity in all brain regions 
studied. HAO activity was reduced by 20-40\, regardless of length of 
preincubation time with r 3 (O, 15, 30 or 60 minutes) (Appendix section, 
Figure 7 and Tables 29-34). In the hypothalamic preparation at least 
30 minutes of preincubation with T3 was required for HAO inhibition. 
Similar results were obtained when preincubation times were O, 
15 or 30 minutes; and whether using c14-tryptamine or cl4_serotonin as 
substrate. 
At the ti.Dle of sacrifice T3 and T4 administered animals were 
found to have a decreased body weight ( 24 + 5 grams), whereas saline 
administered animals gained 54 !.. 11 grams . 
One to eight days of S.C. administra~ion of T3 (l mg/kg/day) 
resulted in no consistent changes in HAO activity when the animals were 
sacrificed 24 hours after the last T3 injection, when cl4-serotonin 
was used as substrate (Table 2). Similar results were obtained when 
cl4-tryptamine was used as substrate and when thyroxine (T4 ) was 
employed instead of T3 (Appendix section, Tables 35, 36, and 37). 
At the conclusion of these in vivo T3 and T4 studies, we 
---
investigated the interactions of T3 administration and subsequent 
protriptyline administration on MAO activity in corpus striatum, forebrain 
and hypothalamus. We chose to use only T3 in these studies since it is 
the more active form of the thyroid hormones and is more potent, faster 
acting and more rapidly metabolized (Tata, 1964; Prange, !!_al., 1970; 
TABLE 2 
Days of 
Injection 
No Injection 
l 
2 
3 
4 
s 
6 
7 
8 
., 
The effect of triiodothyronine on monoamine oxidase activity in three brain regions. 
Corpus Str iatum Forebrain Hypothalamus 
Saline T3 Saline T3 Saline T3 
--------0.460 + 0.03--------- ------0.476 + a.a4------- ------0.256 + 0.02-------
- -
o.543 + .a51• 2 0.4la + .a6 a.729 + .16 0.58a + .la a .2S4 + .a3 a.183 + .02 
-
0.468 + .03 a.so9 + .a6 o.499 + .as 0.493 + .03 0 .264 + .04 0.271 + .03 
-
o.666 + .as 0.622 + .ll 0.761 + .13 0.768 + .13 0.38S + .os 0.310 + .04 
-
o.s10 + .a3 O.S20 + .06 0.601 + .os o.S65 + .03 0.295 + .02 0.2S8 + .02 
-
a.563 + .03 0.42S + .03 0 .670 + .01 0 .575 + .09 0.273 + .03 0.228 + .02 
0.465 + .03 0.568 + .12 0.640 + .a6 0.582 + .04 0 .279 + .03 0.301 + .03 
-
0.603 + .04 O.S98 + .08 0.683 + .07 0.680 + .09 0.299 + .02 0.358 + .03 
- - -
-
0.521 + .04 a.529 + .10 0.719 + .a9 0.838 + .12 0.31S + .03 0 .249 + .03 
- - -
N = 6 for each determination 
lMean !. S.E.H.; Nmoles IAA formed/hour/ug DNA; Serotonin as substrate 
2No statistical significance was observed between any of the time pts. examined 
w 
~ 
Oppenheimer, 1975; Oppenheimer, 1979). No further data involving T~ 
administration are presented. 
35 
The T3 and protriptyline studies were performed since previous 
investigators (Prange,!! al., 1969; Wilson, et al., 1970; Earle, 1970; 
Whybrow, et al., 1972) have documented that thyroid hormone, when 
administered with tricyclics, prcxiuces a quicker clinical improvement 
in depressed patients. In these studies animals were made hyperthyroid 
by seven consecutive S.C. injections of T3 (1 mg/kg/day), a regiment 
previously shown to prcxiuce physiological changes analogous to hyper-
thyroidism (Hammond, 1968; Kennedy, !_!al., 1977). On the seventh day 
following their last T3 injection, animals received one injection of 
protriptyline (10 mg/kg - S.C.);three hours after receiving protriptyline 
all animals had perished;, convulsing prior to death (Table 3). 
The next group of experiments involved simultaneous administra-
tion of r 3 (1 mg/kg - S.C.) and protriptyline (10 mg/kg - S.C.). Six 
hours after the second simultaneous injection of T3 and protriptyline all 
animals perished, convulsing prior to death (Table 4). 
These results (Tables 3 and 4) agree with those of other 
investigators, and suggest that TJ pretreatment enhances the toxicity of 
many centrally acting drugs (Carrier and Buday, 1961; Conney and Garren, 
1961; Prange and Lipton, 1962; Coville and Telford, 1970; Park, et al., 
1972; Breese, !! al., 1974). 
Animals surviving simultaneous administration of protriptyline 
(5 and 1 mg/kg) and T3 (O.l mg/kg), resulted in MAO activity levels which 
TABLE 3 In vivo effects of protrf ptyline administration 
on hyperthyroid animals • 
Protriptyline dosage Results2 
10.0 mg/kg 
5.0 mg/kg 
LO mg/kg 
death within 3 hours 
death within 3 hours 
death within 6 hours 
1Hyperthyroid animals had received 7 consecutive 
injections of T3 (1 mg/kg/day) for 7 days, prior 
to protriptyline administration 
2N = 5 for each group 
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TABLE 4 In vivo toxic effects of simultaneous administration 
Of trITodothyronine and protriptyline on the rat. 
T3 dosage 
Protriptyline dosage (mg/kg/day - s.c.) 1 Results 
Group l 
Group 2 
Group 3 
Group 4 
Group 52 
Group 62 
Group s3 
Group 93 
10.0 1.0 
s.o 1.0 
1.0 1.0 
10.0 o.s 
s.o 0.5 
1.0 o.s 
10.0 0.1 
s.o O.l 
1.0 0.1 
lN = 5 far each group of animals 
death, 2nd day within 
6 hours of injections 
death, 2nd day within 
6 hours of injections 
death, 3rd day within 
6 hours of injections 
death, 3rd day within 
6 hours of injections 
death in 3 of 5 animals 
within 6 hours after 
last injections 
death in 2 of 5 animals 
within 6 hours after 
last injections 
death in 4 of 5 animals 
within 6 hours after 
last injections 
all animals survived 7 
simultaneous injections 
all animals survived 7 
simultaneous injections 
2Groups 5, 6 and 7 MAO activity levels were extremely 
erratic when measured in the respective brain regions 
3Groups 8 and 9 MAO activity levels were again erratic 
and inconsistent 
were not reproducible, between animals of the same group, and were 
inconsistent when one group was compared to another group. 
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Our thyroidectomized (Tx) and sham-operated animals underwent 
surgery at seven weeks of age and eight weeks prior to sacrifice. 
During the eight week time interval, total body weight recordings of 
animal growth were maintained. During this interval Tx animals gained 
approximately 30 .!. 8 grams; paired controls (sham-operated) gained 150 
to 200 grams. This observation, that Tx animals exhibit deficient growth 
patterns, has been previously documented (Fleischmann, 1947; Barker, 
1949; Eayrs and Taylor, 1951). 
The data obtained for MAO activity levels in the three brain 
regions we examined are presented in Table 5. As illustrated in Table 5 
the Tx group clearly exhibits a significant reduction in MAO activity 
levels regardless of substrate employed or brain region examined, when 
these values are compared to age-matched sham-operated controls. 
Since Tx decreased MAO activity in the brain regions we examined, 
our next group of experiments investigated possible changes in MAO 
activity in both Tx and sham-operated animals following protriptyline 
administration (10 mg/kg/day-S.C.). Animals were administered pro-
triptyline acutely (one injection) and subchronlcally (3 or 6 
consecutive daily injections, S .C.). Animals were sacrificed at varying 
time intervals following the last administration of protriptyline. These 
results are presented in the Appendix section (Tables ll, 12 and 13). 
. , 
Substrate 
Tryptamine 
Tryptamine 
Tryptamine 
Serotonin 
Serotonin 
Serotonin 
TABLE 5 The effect of thyroidectorny on HAO activity 
in three brain regions 
Brain Region Tx Sha11 
Corpus Striatum l.90 + 0.141 •2 2.77 + .19 
Forebrain 2.34 + 0.14 3.81 + 0.36 
Hypothalamus 1.68 + o.oa 3.25 + 0.40 
Corpus Striatwn 0.33 + 0.03 o.57 + o.o5 
Forebrain 0.43 + 0.04 0.73 + .07 
Hypothalamus 0.24 + 0.2 0.63 + .09 
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p ~.Ol 
p ~.01 
p ~.02 
p ~.01 
p < .01 
p <,.01 
1Mean .!, S.E.M., nmoles 5-HIAA or !AA formed/hr./ug DNA 
2N = 12 or more animals for each pt. 
Statistically significant differences between groups have been 
indicated; however, MAO activity levels are inconsistent, and no pattern 
for these changes in MAO activities exist. 
2. Norepinephrine levels. 
Prior to determining tissue levels of NE, NE concentrations 
were determined in known standard samples using fluorometric techniques. 
A standard curve was established and has been illustrated in the Appendix 
section (Figure 2«t). Following the determination of the NE external 
standard curve, labelled NE (Dl-H3-norepinephrine) was added to 
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experimental samples to serve as an internal standard for our alumina 
column recovery. These data have been presented in the Appendix section 
(Figure 25}. 
Norepinephrine levels have been quantitatively determined in 
the hypothalamus of T3 pretreated animals, Tx and sham-operated controls. 
These values are illustrated in Figure l. Seven days of s.c. T3 
administration (l mg/kg/day) significantly reduced the NE levels in 
hypothalamus ( p ~ O. 01). On the other hand, neither Tx nor sham-operated 
control animals displayed significantly altered NE levels in hypothalamus. 
Numerical values for these data as well as for corpus striatum and 
forebrain are presented in the Appendix section (Table 38). 
3. Norepinephrine turnover. 
The rate and extent of depletion of NE after administration of 
alpha-methyl-para-tyrosine (HT) (Spector, et al., 1965; Brodie, et al., 
1966; Spector, et al., 1967; Weiner, 1974; Ostman-Smith, 1979), has been 
studied as a measure for assessing NE turnover in control animals (saline 
administered), T3 injected (1 mg/kg/day-7 days), Tx (7 weeks of age, 
8 weeks prior to sacrifice), and in sham-operated Tx controls. 
Prior to assessing NE turnover with MT a dose-response curve 
for tyrosine hydroxylase inhibition was conducted. Literature values 
(Brodie, et al., 1966; Spector, et al., 1967) for effective tyrosine 
hydroxylase (TH) inhibition indicate that 200 mg/kg MT (IP), is necessary 
with an additional booster administration every two hours to maintain 
inhibition. However, a single 400 mg/kg injection of MT will inhibit TH 
for 3.5 hours. The results of our dose-response curve are represented 
FIGURE l 
TITLE: The effect of thyroidectomy and of administration of 
triiodothyronine on norepinephrine levels in the 
hypothalamus 
LEGEND 
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Norepinephrine concentration per gram of tissue wet weight was 
measured in the hypothalamus in animals made hyperthyroid by 7 
days of administration of triiodothyronlne (1 mg/kg seven daily 
injections, S.C.), in animals thyroidectomized at 7 weeks of age, 
8 weeks prior to measurement, and in sham operated controls, in 
comparison to saline injected controls. The cross-hatched band 
illustrates the mean.!. S.E. for saline injected controls (n = 70). 
Vertical bars indicated the mean, S .E. and number of animals in 
each experimental group. The result for the T3 treated group (*) 
is significantly less than control (p ~.01, t-test). 
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in Figure 2. The nW'llerical values for this plot can be found in the 
Appendix section (Table 39). Figure 2 illustrates NE levels in the 
hypothalamus 3 hours after a. MT adrninistrat ion of 200, 4 00, 600 and 8 00 
mg/kg - I.P •• We chose to use the 400 mg/kg dose in NE turnover studies. 
A similar MT dose-response curve was perfarmed for TJ administered 
animals ( l mg/kg/day - 7 days). Triiodothyronine administration in-
creases tyrosine hydroxylase activity (Jacoby, 1975; Strombom, et al., 
1977; Kennedy, !!. al., 1977), and this study was conducted to insure com-
plete tyrosine hydroxylase inhibition at the 400 mg/kg dose. All data 
are presented in the Appendix section (Table 40) for corpus striatum, 
forebrain and hypothalamus. This dose was found to be effective, fully 
inhibiting tyrosine hydroxylase in pretreated hyperthyroid animals. No 
MT dose-response curve was performed for Tx animals. 
Figure 3 reports NE depletion, when 400 mg/kg MT was adminis-
tered to control animals that were sacrificed at varying time points 
after MT administration. The numerical data for each point, slope and 
regression coefficient in this plot, as well as for corpus striatum 
and forebrain (which are not presented graphically) can be found in the 
Appendix section (Table 41). 
Figure 4 reports the results obtained for NE levels in hypo-
thalamus after MT has been administered to hyperthyroid animals (1 mg/ 
kg/day - 7 consecutive days). Numerical values for each point in this 
plot, as well as for corpus striatum and forebrain are listed in the 
appendix section (Table 42). 
FIGURE 2 
TITLE: NE levels in hypothalamus following MT administration: 
A dose-response curve. 
LEGEND 
NE levels were determined in hypothalamic tissue of the rat 
three hours after the administration of various doses of MT 
(200, 400, 600 and 800 mg/kg - I.P.). Each point represents 
the MEAN + S .E. for three or more determinations. There was 
no statistically significant difference in NE levels in hypo-
thalamic tissue following the administration of 400, 600 or 
800 mg/kg MT. 
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FIGURE 3 
TITLE: 
LEGEND 
NE depletion in hypothalamic tissue in control animals 
following administration of MT (400 mg/kg - I.P.). 
NE levels have been determined in control animals at different 
time intervals following the administration of MT (400 mg/kg -
I.P.). Each point represents the MEAN.:!:. S.E. for five or 
more determinations. NE has been maximally depleted 4. 5 hours 
after MT administration at the dosage of HT. 
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FIGURE 4 
TITLE: Turnover of norepinephrine in the hypothalamus of rats 
treated with triiodothyronine. 
LEGEND 
Animals were sacrificed O, 1, 2, 3, 4, 5.or 6 hours after 
administration of a-MT (400 mg/kg, I.P.) and norepinephrine 
levels were measured in the hypothalamus. Each point represents 
the mean and standard error for a group of five animals except 
the zero time point which is derived from a group of 30 animals. 
Triiodothyronine-treated animals (-x-) were injected daily for 
seven days (1 mg/kg, S.C.). 
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Figure 5 depicts the data from Figures 3 and 4 when these 
values are plotted as \ initial concentration of NE. 
The results of NE depletion following administration of MT 
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(400 mg/kg - I.P.) in thyroidectomized. (Tx) animals and age-matched, 
sham-operated. controls are illustrated in Figure 6. Eight weeks after 
Tx, NE turnover is increased.; however, repletion has also occurred more 
quickly. Numerical data for these points, as well as for corpus striatwn 
and forebrain are listed in the Appendix section (Tables 43 and 44). 
D. DISCUSSION 
Our second hypothesis was that simultaneous administration of thyroid 
hormone potentiates the action of TCA drugs through an effect on MAO 
activity, NE turnover and/or NE cellular levels. Our data indicate that 
r 3 administration (l mg/kg/day - 7 days) produces no inhibition of MAO 
activity in vivo, although MAO inhibition was observed. in vitro in these 
brain tissues. Similar results have been reported by other investigators 
for rat .heart and kidney (Callingham and Lyles, 1974; Lyles and Calling-
ham, 1976; Asaad and Clark, 1978). Triiodothyronine administration 
produced. a significant decrease (p ~O.Ol) in NE levels and NE depletion 
(turnover) in these brain regions when canpared to saline administered 
animals. 
Thyroidectomy, on the other hand, was associated with a decrease in 
MAO activity in these tissues. NE levels in these tissues were unchanged, 
however, an increase in both depletion and repletion rates was observed 
following MT administration. 
FIGURE 5 
TITLE: NE depletion in hypothalamus as a measure of \ initial 
concentration three hours after MT administration 
(400 mg/kg - I.P.). 
LEGEND 
In control anir:ials (-0-) NE has been d~pleted 58\ three hours 
after MT administration. In hyperthyroid animals (-x-) NE has 
been depleted 35\ three hours after MT administration (a 23\ 
difference in NE turnover rate). At-test for depletion rate 
resulted in a statistically significant difference between these 
two slopes (p <. 0 .01). 
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FIGURE 6 
TITLE: Turnover of norepinephrine in the hypothalamus of 
thyroidectomized rats. 
LEGEND 
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Animals were sacrificed o, l, 2, 3, 4, S, 6 or 9 hours after 
administration of a-MT (400 mg/kg, I.P.) and norepinephrine levels 
were measured in the hypothalamus. Thyroidectomized animals 
( -x-) and sham operated controls ( -o-) were compared. Each 
point represents the mean and standard error for a group of six 
animals. The values for the thyroidectomized groups at 2, 4, S 
and 6 hours differ significantly from controls (p ~ .OS t-test). 
Regression analysis Ct-test) of the slopes between 0 and 2 hours 
indicated a significant difference (p~ .OS). 
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Also it was observed that when rats are made hyperthyroid by r 3 
administration and are then administered a single injection of protripty-
line, the animals begin to convulse and die within six hours. Similar 
toxic results have been viewed by other researchers when employing · 
imipramine (Prange and Lipton, 1962; Breese, ~al., 1974). This obser-
vation remains unresolved. A possible suggestion for increased 
toxicity may be due to an increased interaction between T3 and increased 
receptor sensitivity in heart tissue to catecholamines (Bax, ~al., 1980; 
Chang and Kunos, 1981), thus accounting for the observed convulsions 
prior to death. 
Reviewing our results, any interaction between thyroid hormone (T3) 
and MAO activity in these brain regions is inconclusive, except for 
significantly decreased MAO levels following thyroidectomy. Zile, 
(1960), has reported that T3 administration does not effect whole brain 
MAO activity; we are in agreement with these results. MAO activity in 
peripheral tissues (heart, liver and kidney) following TJ administration 
however, has been shown to increase (Callingham and Lyles, 1974; Lyles 
and Callingham, 1974; Asaad and Clark, 1978), indicating organ 
specificity. 
We feel our results indicate that T3 does not effect brain MAO 
activity, and any alterations in MAO activity are non-specific. Thus, 
any interaction between the tricyclics and thyroid hormone is not 
related to MAO. 
NE levels and turnover following r 3 administration or after 
thyroidectomy indicate a decrease in turnover in hyperthyroid rats 
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in the brain regions we examined. These results are in agreement with 
Prange, et al..• (1970). We observed decreased NE levels in the brain 
areas of hyperthyroid animals and these results are in agreement with 
Engstrom ( 1974). Landsberg and Axelrod (1968) presented data in heart 
tissue which is in agreement with our data for brain tissue, that 
following thyroidectoray there is increased NE turnover. From these 
results it appears that our observations define situations in which 
adjustments in the parameters of functional norepinephrine activity 
occur contrary to what would be predicted by the NE hypothesis for affec-
tive disorders. We view these contrary changes in neurotransmitter 
parameters as adjustments that are compensatory in nature. Possibly a 
fundamental interaction occurs between thyroid hormone and brain NE 
mechanisms, which leads to an enhanced noradrenergic tone, predicted by 
the NE hypothesis for affective disorders; and that as a result of this 
yet-to-be-identified interaction, a compensatory decrease in NE turnover 
and NE levels result. Conversely, in thyroidectomized animals, the absence 
of this thyroid-hormone-induced facilitation of NE activity likewise 
triggers compensatory adjustments, i.e., decreased HAO activity and 
increased turnover. 
C HAP TE R IV. 
CH APTER IV. 
A. NORLPINEPHRINE: Norepinephrine and its functional relationship 
with the presynaptic receptor. 
1. Norepinephrine levels and turnover. 
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The catecholamines (norepinephrine, epinephrine and dopamine) 
are low molecular weight substances that contain a catechol nucleus and 
an amine group. Norepinephrine (NE), one of these catecholamines, is 
synthesized and secreted by mamalian nerve tissue and serves an 
important function both in neural and endocrine integration. 
The amino acid tyrosine (the substrate precursor to NE) is 
normally present in the circulation in levels between 10-15 mg/l (Spector, 
~ al., 1963). Tyrosine is taken up from the bloodstream and concentrated 
within the brain and other neural tissues via an active transport mech-
anism (Chirigos, !!_al., 1960). Once inside the nerve cell ending or 
chromaffin cell, tyrosine undergoes a series of biochemical enzymatic 
transformations that ultimately lead to NE synthesis. 
Norepinephrine is known by several different names: noradrenaline, 
levarternol and DL-arterenol all of which are trivial names for 3, 4-
dihydroxy-phenyl-ethanolamine (Himms-Hagen, 1967). 
Knowledge of catecholamine synthesis began in the late 1930's 
with the discovery by Holtz (1939) of decarboxylase and by Blaschko's 
(1939) hypothetical but correct, biosynthetic scheme starting from the 
dietary substrate tyrosine. 
Norepinephrine is primarily stored in a bound form in nerve 
cells within chrc:naffin granules or dense-core vesicles (Kirshner, 1974). 
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This bound catecholamine further interacts with adenosine triphosphate 
(ATP) and forms a tetracatecholamine-ATP complex. This salt is further 
bound to soluble proteins, the chromgranins, which are located within 
the storage particle. The inability of labelled exosenuous catechola-
mines to enter these storage granules suggests that the endogenous ATP-
amine complexes are still further combined with macromolecular components 
within the granules and form a still further stable complex (Weiner, 
1970). 
Results also suggest that NE is not located in a single pool, 
but that only a small percentage of neuronal NE is necessary for normal 
neural function (Glowinski, et al., 1966; Sulser and Sanders-Bush, 1970). 
NE thus exists in a large 'storage pool' and a much smaller 'functional 
pool' both of which are located within the nerve cell axoplasm. 
Currently it is suggested that the functional pool contains 
newly synthesized NE, while the sitorage pool contains catecholamine 
which has been in the nerve cell for longer periods of time. This 
assumption is based upon the observation that newly synthesized NE is 
preferentially neleased during enhanced neural firing. Kopin, ~al. 
(1968) has danonstrated that newly synthesized NE is preferentially 
released during stimulation of isolated cat spleen. In vivo studies have 
reported that utilization of newly synthesized NE is increased in response 
to certain stressful conditions; whereas, utilization of NE stored for 
longer time intervals was not affected (Thierry, et al. 1971; Glowinski, 
et al., 1972). 
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Evidenc:e also exists to suggest that in addition to containing 
newly synthesized NE, the functional pool also contains NE which has 
been accumulated via the re-uptake process. Therefore, both newly 
synthesized NE as well as conserved NE are preferentially utilized 
through release in response to i11111ediate stressful conditions (Potter, 
et al., 1962; Chidsey and Harrison, 1963). 
The localization of NE in cell bodies, axons, and axon terminals 
is not random, but regulated by a specific set of chemical laws, which 
are still porrly understood. NE is present mainly in vesicles in nerve 
tissue. These vesicles are distributed along the axon and at the nerve 
endings. NE in these vesicles is in a state of equilibrium with unbound 
NE in the cellular fluids of the cytoplasm. Cytoplasmic NE is available 
for destruction by MAO and for limited leakage or diffusion out of the 
cell. 
NE released presynaptically by stimulation is primarily trans-
ported back into the presynaptic neuron (80\) and is then once again 
bound in these presynaptic vesicles. This prevents degradation by MAO 
and preserves intracellular NE (Kopin, 1966; Titus and Dengler, 1966). 
The re-uptake of NE by active transport and binding into the 
presynaptic vesicles protects NE from depletion and destruction by MAO. 
MAO, therefore plays an important role in the regulation of the "free" 
intracellular levels of NE. Very small quanta of the presynaptically 
released NE reaches the post-synaptic target tissue. Synaptic NE may 
be 0-methylated and excreted, or can be excreted "free" or conjugated 
as glucuronides or sulfonates (Kopin, 1964; Axelrod, 1966). 
' 
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Norepinephrine which has leaked from storage vesicles into the 
axoplasa is rapidly metabolized to physiologically inactive product• 
(Kopin, 196~; Axelrod, 1966). Enzymatic destruction of NE by HAO 
appears to serve primarily as a means for the degradation of NE within 
the cell, thus limiting the concentration of free NE in the inactive 
cytoplasmic compartment and also controlling NE synthesis and the level of 
bound NE. Complete intraneuronal deamination of NE and other catechola-
mines by MAO readily occurs if uptake and storage into synaptic vesicles 
is blocked (i~e. reserpine, or cocaine administration) (Burn and Rand, 
1968; Weiner, 1970). 
Catechol-0-methyl-transferase (COMT), another enzyme responsible 
for the degradation of catecholamines, is apparently unimportant in the 
metabolization of intraneuronal NE. COMT is significantly involved in 
the catabolism of circulating catecholamines, which occurs chiefly in 
the liver and kidney. 
The third hypothesis this research attempts to investigate 
relates changes in cellular NE levels and turnover to acute subchronic 
and chronic tricyclic administration, and these changes parallel their 
delayed clinical efficacy. As stated earlier the "catecholamine 
hypothesis for affective disorders" proposes that some, if not all 
depressions are associated with an absolute or relative deficiency of 
catecholamines, particularly NE, at the functionally important adrenergic 
receptor sites in the brain. Consequently, studies have shown that drugs 
which cause depletion and inactivation of NE in brain produce sedation 
or depression, whereas, drugs which increase or potentiate brain NE are 
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associated with behavioral stimulation or excitation and. generally produce 
or exert an antidepressant effect in man. 
Because a lag-time ls evident between tricyclic administration and 
clinical efficacy (Schildkraut, et al., 1970; Schildkraut, .!! al., 1971; 
Sulser and Sanders-Bush, 1971; Leonard, 1975; Leonard and Kafoe, 1976; 
and Berger, 1978),this aspect of this study will examine possible changes 
in intracellular NE and also turnover rates and attempts to observe if 
these changes parallel the time course for clinical efficacy for this 
class of antidepressant agents. 
Because brain NE levels are maintained constant in the face of 
conditions which alter nerve firing rate, it has been suggested that NE 
which is utilized during enhanced neuronal firing is replaced by an 
increase in NE synthesis (Weiner, 1970; Costa and Meek, 1974; Bjorklund, 
~al., 1976; and Ostman-Smith, 1979). This compensatory mechanism 
has been termed "the theory of steady-state kinetics." 
The mechanism by which increased noradrenergic nerve activity 
results in the stimulation of increased NE synthesis is not known. The 
most concrete explanation however, is that nerve stimulation releases NE 
from a nerve terminal, which consequently results in decreased intra-
neuronal NE concentrations. Since NE competetlvely inhibits its own 
synthesis by interfering with the pteridine cofactor required by tyrosine 
hydroxylase (Udenfriend, et al., 1965; Gordon, !! al., 1966; Kennedy, et 
al., 1977), nerve stimulation would result in a decrease in negative 
feedback inhibition of tyrosine hydroxylase. The converse also applies 
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(Spector, !!_al., 1965; Spector, 1966; Spector, et al., 1967; and 
Weiner, 1970). It is therefore appropriate for one to conclude that NE 
synthesis is controlled by a small, chemically undetectable pool of intra-
neuronal cytoplasmic NE. 
The term "turnover" refers to a process of renewal of a substance 
in an organ. The concept of turnover implies that the substance being 
renewed exists at some steady-state level, which is balanced by identical 
rates of influx and efflux. In the case of brain NE the rate of NE 
influx equals the rate of NE syntehsis, since endogenous NE cannot enter 
the brain via the circulation due to the blood-brain barrier (Dobbing, 
1961; Guroff and Udenfriend, 1962; Bertler, et al., 1966; and Oldendorf, 
1974). The rate of efflux is determined by release of NE into the circu-
lation and resultant metabolic destruction by MAO or COMT. Assuming that 
NE levels are maintained at some steady-state value, the NE influx rate 
(synthesis rate) would equal the NE efflux rate. Then this rate, which 
may be estimated by any method which can measure NE turnover, would 
give the investigator an indication of the rate at which brain NE is 
synthesized and utilized, which then, may be used as an indicator of 
central noradrenergic activity. 
Many methods for measuring NE turnover exist and have been 
reviewed extensively by others (Costa and Neff, 1968; Costa, 1970; Costa 
and Neff, 1970; and Weiner, 1974). The method employed here is a 
measure11ent of the rate of decline of endogenous brain NE after inhibition 
of tyrosine hydroxylase by alpha-methyl-para-tyrosine. This method was 
first described by Brodie, et al., (1966). 
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Synthesis inhibition is accomplished by employing alpha-methyl-
para-tyrosine, (MT), an in vivo reversible inhibitor of tyrosine hydroxy-
las• (TH), the rate-limiting step in NE synthesis (Spector, et al., 
1965; and Spector, 1968). After blockade of NE synthesis, brain NE 
levels decline in a monoexponential fashion (Brodie, et al., 1966), 
i.e. the concentration of NE declines at a rate that is proportional to 
the NE concentration remaining in the neuronal cytoplaSTI at any given time. 
This phenomena may be viewed as "the rate of NE utilization," and at the 
steady-state, "the rate of synthesis," which is proportional to cyto-
plasmic NE concentrations. 
Therefore it was imperative that we investigate the noradrenergic 
effects caused by tricyclic administration during acute, subchronic and 
chronic treatment schedules, and thus possibly identify biochemical 
changes in NE levels and turnover rates. These data may then add support 
in identifying noradrenergic mechanisms necessary for latent clinical 
efficacy. 
2. Presynaptic autoreceptor modulation of noradrenergic mechanisms. 
Before introducing the concept "presynaptic alpha-receptors" 
(Norberg and Hamerger, 1964; Langer, 1974; Berthelsen and Pettinger, 
1977; Malbon, 1979; U'Prichard and Synder, 1979), it is first necessary 
to examine the processes involved in NE release from presynaptic nor-
adrenergic nerve terminals. NE is synthesized from the amino acid 
tyrosine, and is stored in vesicles in the neuroplasm. These vesicles 
in turn migrate to the nerve cell membrane, and release transmitter 
when an action potential arrives. It has also been demonstrated that an 
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influx of calcium into the neuroplasm causes these NE containing 
vesicles to migrate to the neuronal membrane (Rubin, 1970; Blaustein, 
et al., 1972; Phillis, 197~). The mechanism involved in this migration 
- -
is still unclear. At the manbrane, fusion occurs. and these vesicles 
discharge their contents into the synaptic cleft. These vesicles then 
re-form after discharge and are again filled with transmitter fra1 the 
neuroplasm. 
Brown and Gillespie (1957) first suggested that this release may 
be modulated by another mechanisa, in addition to the arrival of an 
action potential. They also noted that the alpha-blocking agent pheno-
xybenzamine increased the overflow of NE in cat spleen caused by 
repeated nerve stimulation. 
Other studies conducted by Starke, et al., ( 1971); and Enero, 
et al., (1972) using other alpha-receptor blocking agents also caused 
an increase in overflow of transmitter following repeated nerve stimula-
tion. These observations led to the hypothesis that alpha-receptors 
are present in the outer surface of adr ~ -nembranes of neurons and 
are involved in the regulation of NE relaase via a negative feedback 
mechanism. Thus, as NE is released into the synaptic cleft, it tends to 
limit its own release, by stimulating a presynaptic inhibitory alpha-
receptor {Kirpekar and Puig, 1971; Starke, 1972; Starke and Schumann, 
1972; Rochette, et al., 1976; Lorenz, et al., 1979). This phenomenon 
occurs in peripheral tissues as well as in the CNS (Bunney and Aghajanian, 
1975; Carlsson, 1975; Roth, !! al., 1975; Strombom, 1975; I.anger and 
Dubocovich, 1977; Baraban and Aghajanian, 1980). When presynaptic alpha-
receptors are stilllulated by an appropriate agonist or blocked by an 
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appropriate antagonist (oxymetazoline, phenoxybenzamine, or phentolamine) 
(Kapur and Mottram, 1978; l<alsner and Chan, 1979; Werner, et al., 1979; 
Baraban and Aghajanian, 1980) the negative feedback mechanism inhibiting 
or facilitating NE release is altered. The sequential release of NE 
resulting in transmitter overflow thus occurs "or" is prevented. It 
also appears that the presynaptic alpha-receptors modulate the release 
of NE by controlling the influx of calcium into the presynaptic nerve 
ending (Langer, et al., 1975). In summary, the presynaptic alpha-
receptor mediates NE release, which is dependent upon synaptic neuro-
transmitter concentrations, and a functionally operative negative 
feedback mechanism. Activation of presynaptic alpha-receptors (auto-
receptors) leads to a decrease in transmitter release, while blockade 
of these alpha-receptors results in an increase of NE release following 
nerve stimulation (overflow) (Langer, 1974; Langer, 1977; Starke, et al., 
1977). 
The physiological and biochemical events reulting from the 
activation or inactivation of alpha-receptors in the CNS remains unclear. 
Some evidence (Segal, et al., 1975; Greengard, et al., 1976; Skolnick and 
Daly, 1977; l<anof and Greengard, 1978; Hall and Ogren, 1981) in tu=n 
activates cyclic-AMP generating systems. Other studies (Glauhiger and 
Lefkowitz, 1977; Williams and Lefkowitz, 1977) indicate that the number 
of CNS alpha-receptors can be altered in .a variety of brain areas by 
chronic treatment with specific drugs and hormones, which in turn 
results in altered CNS mechanisms. Still other studies suggest that 
drugs and hormones may sensitize or desensitize these pre- and post-
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synaptic alpha-receptOPs (Comsa, 1950; Thibault, 1956; Potter, et al., 
1962; Haggendal and Lindqvist, 1964; Lee, et al., 1967; Lipton, et al., 
1968 ; Prange, et al. , 197 0) • 
It was our intent in this study to examine the effects of the 
alpha-receptor antagonist (yohimbine) on NE levels and turnover following 
chronic tricyclic administration. 
Several studies have indicated that chronic administration of 
tricyclics cause changes in NE levels and NE turnover in brain and other 
tissues (Schildkraut, !!_al., 1970; Schildkraut, et al., 1971; Roffler-
Tarlov, et al., 1973; Leonard and Kafoe, 1976; Anden and Grabowska, 1977; 
Frazier, et al., 1978; Svensson and Usdin, 1978). Since chronic 
tricyclic treatment is necessary. for therapeutic results, it has been 
suggested that a slow developing adaptive process at the level of the 
autoreceptor may be occurring (Vetulani, et al., 1976; Crews and Smith, 
1978; Sulser, et al., 1978; Bergstrom and Kellar, 1979; Collis and Shep-
herd , 198 O ). 
We felt that if receptor adaptation occurs with chronic tricyclic 
treatment, employing yohimbine would allow us the opportunity to observe 
these changes in both NE levels and turnover rate. These results would 
then allow us to specifically test whether adaptive changes in presynaptic 
receptors might be an important component of the mechanism of chronic 
tricyclic action. 
B. METHODS AND PROCEDURES 
Initial experiments involving NE levels and turnover were performed 
in three areas of rat brain (corpus striatum, forebrain, and hypothalamus) 
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in control animals {saline injected), protriptyline administered 
(10 mg/kg/day for l, 3, 6, and 18 days) and in thyroidectomized animals 
which also received protriptyline acutely, subchronically and 
chronically. 
With the conclusion of these studies, the examination of both 
corpus striatWri and forebrain was discontinued, since the primary 
neurotransmitter in the corpus striatum is dopamine (Hillarp, et al., 
1966; Snyder and Coyle, 1969; Iversen, 1973; Hornykiewicz, 1973; Harris 
and Baldessarini, 1973), and 5-hydroxytryptamine {serotonin) for 
forebrain (Schwark and Keesey, 1975; Saavedra, et al., 1976; Bjorklund, 
et al., 1976). It was felt that further examination of these tissues 
would be unnecessary, and unrelated to the effects of chronic protripty-
line administration on norepinephrine turnover. All studies involving 
yohimbine are performed only with hypothalamic tissue preparations. 
We chose to examine only the hypothalamus in our receptor-interaction 
studies because we considered the hypothalamus an important target tissue 
for the actions of protriptyline. This area of the brain is responsible 
for many neuroendocrine transmitter interactions (Stokes, !!._al., 1981) 
as well as regulating or modulating both physiological and emotional 
responses (Kordon and Glowinski, 1970; Dewhurst, et al., 1968; Kobayashi, 
et al., 197~, de la Fuente, 1979). 
Yohimbine our presynaptic autoreceptor antagonist was obtained from 
Sigma Chemical Company, St. Louis, Missouri. 
Our experimental protocol for drug administration involving our 
norepinephrine turnover studies is complicated and has been diagrammed 
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below for better understanding. This procedure allowed us to examine 
norepinephrine turnover when protriptyline and or our test drug, 
yohimbine, were at maximal plasma levels and optimally effective. 
~.o 
time since 
last Prot. 
admin. 
(usually 
test drug 
admin. 
(saline) 
(yohimbine) 
MT 
admin. 
Time (hours after MT 
administration) 
three 
hours) 
C. RESULTS 
l. Protriptyline, NE levels and turnover. 
NE levels were determined in corpus striatum, forebrain and 
hypothalamus following l, 3, 6 and 18 days of protriptyline administra-
tion (10 mg/kg/day - S.C.). The data obtained for these determinations 
are presented in Figure 7. The numerical values for NE determinations 
for corpus striatum and forebrain are presented in the appendix section 
(Tables 45 and 46). A statistically significant difference from control 
animals was recorded in NE levels in the hypothalamus when protriptyline 
treated animals were sacrificed 3 hours after the last test drug 
injection in both the acute and chronically administered protriptyline 
animals (p£ 0.01). Chronic protriptyline administration also resulted 
in a statistically significant difference in NE levels in corpus striatum 
(pL0.01). In the hypothalamus a 26% decrease in NE levels was recorded 
following acute drug administration and a corresponding 30% decrease in 
69 
FIGURE 7 
TITLE: Norepinephrine levels in hypothalamic tissue following 
acute, subchronic and chronic protriptyline administration 
LEGEND 
Animals were administered protriptyline 1, 3, 6 and 18 consecutive 
days (10 mg/kg/day - S.C.). All animals were sacrificed 3 hours 
after their final drug administration. Acute and chronic 
protriptyline administration caused a statistically significant 
decrease in NE levels in hypothalamic tissue (p~0.01) when compared 
to saline administered controls. 
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NE levels was observed following chronic administration. Similar 
• 
results have been reported by others examining whole brain preparations 
(Schildkraut, et al., 1970; Schildkraut, et al., 1971; Roffler-Tarlov, 
et al. , 197 3 ) • 
Figure 8 presents data for NE depletion in hypothalamic tissue 
following acute protriptyline administration (10 mg/kg - S.C.), and 
followed by MT administration (400 mg/kg - I.P.). MT was administered 
three hours after protriptyline. These animals were sacrificed at 
various times after MT administration. A t-test for comparison of 
depletion rates between saline administered (Figure 3) and acute 
protriptyline administration resulted in a statistically significant 
difference in turnover rate (p4'_0,005). This result is consistent with 
Leonard and Kafoe (1976). Numerical values for these data are listed 
in the appendix section (Table 47). 
Figure 9 presents data for NE depletion in hypothalamic tissue 
following subchronic (6 consecutive daily injections) protriptyline 
administration (10 mg/kg/day - S.C.). MT was administered 6 hours after 
the last protriptyline injection. Animals were sacrificed at various 
times after MT administration. A t-test for the comparison of depletion 
rates between saline administered and protriptyline administered animals 
resulted in a statistically significant difference in depletion rate 
between groups (p <.0.01). Numerical values for each time point are 
listed in the appendix section (Table 48). 
FIGURE 8 
TITLE: Norepinephrine depletion in hypothalamic tissue following 
acute protriptyline administration 
LEGEND 
72 
Animals were administered MT three hours after an acute administra-
tion of protriptyline. Animals were sacrificed o, l, 2, 3, 4.5, . 
and 6 hours after subsequent MT administration. Each point 
represents the MEAN + S.E. for 3 or more experiments. 
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FIGURE 9 
TITLE: Norepinephrine depletion in hypothalamic tissue following 
subchronic protriptyline administration 
LEGEND 
Animals received six consecutive injections of protriptyline 
(10 mg/kg/day - S.C.). MT was administered six hours after the 
final protriptyline injection. Animals were sacrificed O, 1, 2 
and 3 hours after MT administration. All points represent the 
MEAN + S.E. of at least 3 or more experiments. 
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A MT dose-response curve was conducted on chronically treated 
protriptyline animals prior to examining NE turnover. Figure 10 
presents our results for NE depletion in chronically treated protr_ipty-
line animals following the administration of various doses of MT (200, 
400, 600 and BOO mg/kg). Numerical values for each data point in 
this figure are presented in the appendix section (Table 51). These 
data suggest that tyrosine hydroxylase (TH) is completely inhibited 
three hours after MT administration at any of the above doses. Thus, 
the 400 mg/kg dose was employed for our turnover studies in chronically 
administered animals. 
Figure 11 represents NE depletion in hypothalamic tissue following 
18 days of chronic protriptyline treatment. Numerical data for each 
time point are listed in the appendix section (Table 52). 
Figure 12 is a composite of the data recorded in Figures 3 
and 11. The decrease in NE depletion following chronic protriptyline 
administration becomes more evident. A t-test on the comparison of 
turnover rates between these two conditions between zero time after MT 
administration and three hours after MT administration indicate that a 
statistically significant difference exists between these two groups 
(pL 0.01). After the three hour time point values were not included in 
the depletion rate calculations. 
When the data in Figure 12 are plotted as "percent of initial 
concentration of NE" (Figure 13), MT administration causes a 58% 
depletion in NE in saline administered animals when these animals are 
sacrificed three hours after MT administration. A 22% decrease in NE 
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FIGURE 10 
TITLE: HT dose-response curve in animals administered protriptyline 
chronically 
LEGEND 
Animals received protriptyline chronically (10 mg/kg/day, 18 days) 
and were then administered various doses of MT three hours after 
the final protriptyline injection. Animals were sacrificed three 
hours after receiving MT (200, 400, 600 or 800 mg/kg - I.P.). 
Each data point represents the MEAN + S.E. of at least 4 experi-
mental determinations. No statistically significant difference 
in NE depletion was observed between any of the MT doses examined. 
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FIGURE 11 
TITLE: Norepinephrine depletion in hypothalamic tissue of 
animals receiving chronic protriptyline administration 
LEGEND 
79 
Animals received protriptyline chronically (10 mg/kg/day, 18 days) 
and 3 hours after the final protriptyline injection, they were 
administered MT (400 mg/kg - I.P.). Animals were sacrificed at 
various times after MT administration (O, 1, 2, 3, 4.59 . 6 and 9 
hours). Each point represents the MEAN+ S.E. for at least 4 
experimental determinations. 
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FIGURE 12 
TITLE: A comparison of turnover rates in hypothalamic tissue 
in rats administered protriptyline or saline chronically 
LEGEND 
Animals were administered protriptyline (10 mg/kg/day, 18 days) 
(-x-) or saline (-0-). Three hours after the final injection of 
protriptyline or saline, animals were administered MT (400 mg/kg -
I.P.). Animals were sacrificed at various times after MT administra-
tion (0, 1, 2, 3, 4.5, 6 and 9 hours). All values represent the 
HEAN + S.E. for at least 3 experimental determinations. A t-test 
for comparison of depletion rates between 0 and 3 hours after HT 
administration indicates taht a statistically significant difference 
existed in depletion rate between these two groups (p L0.01). 
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is observed in the hypothalamus when chronically treated protriptyline 
animals are sacrificed three hours after HT administration. A 36% 
difference in NE depletion is recorded between these treatment conditions. 
Tables 6 and 7 list both the slope and regression coefficient 
for saline and protriptyline treated animals. Table 57 in the appendix 
section presents the statistical results when NE depletion was compared 
between these two groups. 
Figure 14 is a turnover rate/recovery rate plot for the data 
presented in Tables 6 and 7. These data suggest that adaptations in 
NE turnover rate/recovery rate have resulted from chronic protriptyline 
administration. 
A t-test for the comparison of turnover rate/recovery rate 
indicated that acute turnover rate/recovery rate is significantly 
different when compared to either subchronic or chronic turnover rate/ 
recovery rate (p"90.001). No statistically significant difference was 
observed when subchronic administration was compared to chronic ad-
ministration for turnover rate/recovery rate. 
2. Yohimbine studies and norepinephrine turnover. 
Studies determin~ng NE levels and turnover following yohimbine, 
protriptyline and MT administration were conducted. The first plot 
(Figure 15) employing yohimbine illustrates the effects of a single 
injection of yohimbine on NE levels in the hypothalamus of control ani-
mals. In Figure 15 yohimbine, using either a 2.0 mg/kg and 20.0 mg/kg 
dose, depletes hypothalamic tissue levels of NE. The 20. O mg/kg dose, 
however, depletes NE for a longer time interval. In Figure 15 a 56% 
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FIGURE 13 
TITLE: NE depletion as a measure of % initial concentration in 
LEGEND 
the hypothalamic tissue of chronically treated protriptyline 
or saline animals 
Animals received protriptyline (10 mg/kg/day, 18 days) or saline, 
and were then administered MT 3 hours after the final protriptyline 
or saline injection. Animals were sacrificed three hours after MT 
administration. NE levels in protriptyline treated animals (-x-) 
was depleted 22% and in saline administered animals (-0-) a 58% 
depletion in NE level was recorded. 
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TABLE 6 A comparison of slope and linear regression co-
efficients for saline treated animals following 
administration of MT (400 mg/kg - I.P.) 
Saline 
Acute 
(1 injection) 
hours after last prot. 
admin. 
3 hours 
6 hours 
Subchronic 
( 6 injections) 
hours after last prot. 
admin. 
6 hours 
Chronic 
(18 injections) 
hours after last prot. 
admin. 
6 hours 
24 hours 
Slope* 
-0.6074 
-0.6528 
-0.5212 
-0.5912 
-0.6543 
MEAN -0.6054 
S.D. 0.0546 
S.E.M. 0.0244 
0. 9825 
0.9575 
0,9677 
0.9873 
0. 9219 
86 
*These determinations were calculated from the MEAN and S.E. 
from the previous independent experiments 
hours 
TABLE 7 A comparison of slope and linear regression co-
efficients for protriptyline treated animals 
following administration of HT (400 mg/kg - I.P.) 
Protriptyline Slope* . (r2)* 
Acute 
(1 injection) 
after last prot. 
admin. 
3 hours -0.1475 0.6213 
6 hours -0.1336 0 .8512 
24 hours -0. 5241 0.9284 
Subchronic 
(6 injections) 
87 
hours after last prot. 
admin. 
2 hours -0.2319 0,9100 
6 hours -0. 2471 0,8449 
24 hours -0.3064 0,9313 
Chronic 
(18 injections) 
hours after last prot. 
3 
6 
24 
admin. 
hours -0.1897 0.9331 
hours -0.2734 0.7809 
hours -0.2234 0.2790 
*These determinations were calculated from the HEAN and S.E. 
from the previous independent experiments. 
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FIGURE 14 
TITLE: Turnover rate/recovery rate for NE in rat hypothalamic 
tissue following acute, subchronic and chronic protriptyline 
administration 
LEGEND 
The turnover rate/recoveryrate for NE in rat hypothalamic tissue 
following acute, subchronic and chronic protriptyline administration 
has been plotted and the slope for these 3 injection schedules has 
been determined. The acute turnover rate/recovery rate slope (-t:::I-) 
is significantly different (pL..0.001) from either subchronic turn-
over rate/recovery rate (-x-) or chronic turnover rate/recovery 
rate (-o-). 
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FIGURE 15 
TITLE: Norepinephrine depletion in hypothalamic tissue following 
yohimbine administration 
LEGEND 
Animals were administered yohimbine (2.0 mg/kg or 20.0 mg/kg) 
and were sacrificed O, l, 2.5 and 5 hours after this administration. 
All points represent the MEAN + S.E. for at least 4 experimental 
determinations. 
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decrease in NE is reported following a single administration of 
yohimbine at 20,0 mg/kg. Similar results have been reported by Papeschi 
and Theiss (197S) in whole brain preparations. A 20.0 mg/kg dose was 
employed for our future studies, since it allowed a longer time interval 
for the measurement of turnover following MT administration. Numerical 
values for each time point are presented in the appendix section 
(Table S3). 
Figure 16 illustrates the effects of yohimbine and MT 
administration on NE levels in ·Control animals. NE levels in the 
hypothalamus are maximally depleted one hour after MT administration, 
and two hours after yohimbine administration. The 6S% depletion in NE 
levels is not recorded in saline administered animals which received 
MT. Numerical values for these data are presented in the appendix 
section (Table S4), 
Figure 17 reports the effects of a single administration of 
yohimbine (20.0 mg/kg) on animals which have been chronically adminis-
tered protriptyline (10 mg/kg/day, 18 days). Animals were administered 
yohimbine three hours after the final protriptyline injection. This 
plot illustrates that three hours after yohimbine administration NE 
levels do not deplete in the hypothalamus. This result contrasts with 
our observation in Figure lS, In Figure lS, yohimbine administration 
resulted in a S6\ decrease in NE levels. The numerical values for 
Figure 17 are presented in the appendix section (Table SS). 
Figure 18 presents data illustrating the effects of both 
yohimbine and MT administration on NE levels following chronic 
FIGURE 16 
TITLE: NE turnover in hypothalamus of animals which have 
received yohimbine and sequentially MT 
LEGEND 
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Animals were administered yohimbine (20 mg/kg - I.P.) and one hour 
later MT (400 mg/kg - I.P.). Animals were then sacrificed O, 
1, 2, 3, 4.5 and 6 hours after MT administration. Each data 
point represents the MEAN + S.E. for at least 4 experimental 
determinations. 
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FIGURE 17 
TITLE: NE depletion in the hypothalamus of animals receiving 
chronic protriptyline treatment and then administered 
yohimbine 
LEGEND 
Animals received protriptyline (10 mb/kg/day - 18 days S.C.) and 
three hours after their final protriptyline injection they 
received yohimbine (20 mg/kg, I.P.). These animals were 
sacrificed o, 1, and 3 hours a~ter yohimbine. Each data point 
represents the HEAN + S.E. for at least 4 experimental 
determinations. 
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FIGURE 18 
TITLE: NE depletion in hypothalamus following chronic 
protriptyline administration, yohimbine administration 
and MT administration 
LEGEND 
97 
Animals were administered protriptyline chronically (10 mg/kg/day, 
18 days - S.C.). Three hours after the final protriptyline 
administration animals were administered yohimbine (20 mg/kg) 
I.P •• One hour after yohimbine administration animals were adminis-
tered MT (400 mg/kg - I.P.). Animals were then sacrificed o, 
1, 2, and 3 hours after MT administration. Each data point 
represents the HEAN + S.E. for at least 4 experimental 
determinations. 
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protriptyline administration (10 mg/kg/day, S.C. - 18 days). Three 
hours following MT administration, NE levels were not statistically 
different from the NE levels reported following chronic protriptyline 
administration and subsequent HT administration (see Figure 11). 
This study indicates that the effects of yohimbine appear nullified 
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when protriptyline has been administered chronically. In control 
studies, it should be recalled that NE was depleted 56% and 70% three 
hours after yohimbine administration (Figures 15 and 16). Numerical 
values for each time point are listed in the appendix section (Table 56). 
D. DISCUSSION 
To test our third hypothesis "that chronic protriptyline 
administration may induce changes in specific NE ?arameters and the 
presynaptic autoreceptor" studies were designed to evaluate changes 
in NE levels and turnover, employing the alpha-receptor antagonist 
yohimbine after chronic protriptyline administration. The results of 
these studies strongly suggest that chronic administration of protripty-
line alters presynaptic alpha-receptors. Chronic protriptyline ad-
ministration decreases NE levels in the hypothalamus; a finding which 
at first seems contradictory to the "catecholamine hypothesis of 
affective disorders", which suggests that increased NE at post-synaptic 
receptor sites is required to alleviate depression. Increased neuro-
transmitter levels would indicate increased release following an action 
potential, and decreased NE levels would indicate decreased neuro-
transmitter release. 
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Secondly, chronically administered protriptyline decreases NE 
turnover when compared to control animals, and exhibits increased 
turnover when compared to acute protriptyline administration. This 
result also seems contrary to the "catecholamine hypothesis of affective 
disorders" since one would predict that increases in turnover (i.e. 
synthetic rate) are necessary (to alleviate depression) to maintain the 
constant efflux of NE to the post-synaptic receptor. 
Thirdly, yohimbine administration {which in control animals 
illicited NE depletion), to chronically administered protriptyline 
animals has no effect or minimal effects on NE depletion (Figure 17). 
This suggests that chronic protriptyline administration may produce 
subsensitivity of alpha-2-(presynaptic)-receptors, which in turn 
modify NE release to the synapse. 
These results suggest the existence of presynaptic alpha-2-
receptors are undergoing adaptation when protriptyline is administered 
chronically to experimental animals. The implications of these adaptive 
mechanisms and their relationships to the catecholamine hypothesis of 
affective disorders will be discussed in Chapter v. 
C H A P T E R V 
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CH APTER V. 
A. SUMMARY AND CONCLUSIONS 
Our studies attempted to identify possible alternate mechanisms of 
action in the CNS when the tricyclic, protriptyline, was administered 
chronically to rats. These studies also examined the effects of both 
protriptyline and thyroid hormone administration on monoamine oxidase 
(HAO) activity. The following results were observed: 
(1) In vitro preincubation with protriptyline inhibits MAO 
activity in all three brain regions examined. 
(2) In vivo administration of protriptyline has varying and 
InconsTstant effects on MAO activity. 
(3) Monoamine oxidase activity is inhibited in vitro by 
preincubation with triiodothyronine. 
(4) Triiodothyronine administration has no in vivo effect 
on HAO activity in the three brain regions-examined. 
( 5) Thyroidectomy decreases MAO activity in all three brain 
regions examined. 
(6) The simultaneous administration of protriptyline and 
triiodothyronine have toxic lethal effects on animals when 
administered at the dose ranges we examined, and in those 
animals which survived simultaneous administration, 
monoamine oxidase data was inconsistent and inconclusive. 
(7) Protriptyline administration to thyroidectomized animals 
results in variable and inconsistent effects on MAO 
activity. 
Several of these observations (1, 3, 4) have been documented by 
others (Gabay and Valcourt, 1968A; Roth and Gillis, 1974A; Roth, 
1977). In addition, other animal studies have documented toxic effects 
of concurrent triiodothyronine administration with the tricyclic 
lmipramine, or with other pharmacological agents (Carrier and Buday, 
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1961; Conney and Garren, 1961; Prange and Lipton, 1962; Coville and 
Telford, 1970; Breese, et al., 1974). No documentation could be 
found identifying toxic interactions when protriptyline was 
administered with triiodothyronine. 
At the completion of these studies it was concluded that any 
interaction between protriptyline and MAO activity was non-specific 
and our first hypothesis "that the requirement for chronic treatment 
with tricyclics before clinical efficacy is observed is related to 
an action on mitochondrial MAO, and that the time course for this 
effect parallels the time course for clinical response" was incorrect. 
Similarly, the toxic interactions of simultaneous triiodothyronine 
and protriptyline administration, though of interest, also remain 
unresolved. 
Continuing, we next examined the effects of thyroidectomy and 
both triiodothyronine (T3) and protriptyline administration on NE 
levels and turnover. We observed the following results: 
(1) That seven days of triiodothyronine administration 
(1 mg/kg/day) results in decreased NE pool size in 
the brain areas examined. 
( 2) That thyroidectomy induces ~ change in NE pool size in 
these same brain regions. 
(3) That both acute and chronic protriptyline administration 
(10 mg/kg/day) result in decreased NE pool size. 
( 4) That NE turnover is decreased in tr iiodothyronine treated 
animals when compared to saline administered control 
animals. 
(5) That NE turnover in thyroidectomized animals is increased 
when compared to Sham-operated control animals. 
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(6) That NE turnover in the hypothalamus of both acutely and 
chronically administered protriptyline rats is decreased 
when compared to saline administered control animals. 
The possible physiological significance of alterations in brain 
NE levels and turnover after triiodothyronine administration, and 
following acute and chronic protriptyline administration may be postu-
lated to be related to compensatory and adaptive mechanisms, resulting 
from changes in noradrenergic alpha-receptor sensitivity. Decreases 
in both NE levels and turnover were observed after seven days of T3 
administration. Our observation of both a decrease in NE level and 
decreased turnover would be explicable if T3 induces increased receptor 
sensitivity to NE. Increased receptor sensitivity would allow a decrease 
in the amount of NE released into the synapsis and still illicite a 
target cell response. Increased receptor sensitivity induced by T3 
has been documented (Engstrom, et al., 1974; Engstrom, et al., 1975; 
Strombom, et al., 1977). 
Increased receptor sensitivity may also be responsible for the 
toxic side effects of protriptyline. Long (1977) has reported animal 
results in which heart palpitations and arrhythmias have occurred when 
T3 was administered with other pharmacological agents. Possibly T3 
increases receptor sensitivity and sequential protriptyline administra-
tion results in an increase ' in toxic effects. 
Both acute and chronic protriptyline administration induced changes 
in NE levels and turnover in hypothalamus. The acute effects of the 
tricyclics on brain noradrenergic parameters have been documented by 
many investigators (Schildkraut, et al., 1970; Schildkraut, et al., 
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Roffler-Tarlov, et al., 1973; Leonard and Kafoe, 1976). Decreases in 
NE levels have been postulated to result from the negative feedback 
inhibition by NE on tyrosine hydroxylase (TH) activity, via the pteridine 
cofactor site. Decreased turnover also results from negative feedback 
inhibition. Alternations in both of these noradrenergic parameters 
result from the tricyclics primary mechanism of action (re-uptake 
blockage) and may be viewed as compensatory noradrenergic neural 
adjustments. 
In our chronic protriptyline studies we observed decreased 
hypothalamic tissue levels of NE and also a decrease in NE turnover rate 
compared to chronic saline administered controls. These results suggest 
a decrease in NE synthetic rate. Other investigators have also demon-
strated changes in other noradrenergic parameters which also suggest 
decreased synthetic rate. Handel, et al., (1973) demonstrated that chronic 
imipramine treatment decreases midbrain tyrosine hydroxylase (TH) 
activity. Schildkraut (1965) and Schildkraut, et al., (1972, 1975) 
demonstrated that chronic treatment with amitriptyline or imipramine 
decreased the excretion rate of norepinephrine metabolites in the CSF. 
We postulate that the observed decrease in NE levels and turnover rate 
is an adaptive response resulting from increased efficiency of transmission 
as a consequence of re-uptake blockade. 
Our studies suggest that adaptations in the presynaptic alpha-
receptor in the hypothalamus have occurred following chronic protriptyline 
administration. In our final studies we employed yohimbine in an attempt 
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to further examine whether alpha-receptor adaptations have occurred and 
whether such changes correlate with the lag-time observed for clinical 
efficacy. 
The following results were obtained when yohimbine was employed: 
(1) Yohimbine administration (20.0 mg/kg, I.P.) produced 
a 56% decrease in total cytoplasmic NE levels in control 
animals three hours after test drug administration. 
(2) Yohimbine administration (20.0 mg/kg, I.P.) to chronically 
treated protriptyline (10 mg/kg, 18 days, S.C.) 
animals produced NO decrease in total cytoplasmic NE 
levels three hourS--after test drug administration. 
(3) Yohimbine administration (20.0 mg/kg, I.P.) followed by 
alpha-methyl-para-tyrosine (MT) administration (400 mg/ 
kg, I.P.) to control animals resulted in a 72% decrease 
in total cytoplasmic NE levels three hours after MT 
administration. 
(4) Yohimbine administration (20,0 mg/kg, I.P.) followed by 
MT administration (400 mg/kg, I.P.) to chronically 
treated protriptyline animals (10 mg/kg, 18 days, S.C.) 
produced a 40% decrease in total cytoplasmic NE levels 
three hours after MT administration. 
These results can be explained in the following manner. Yohimbine, 
a pre-synaptic alpha-receptor antagonist, suppresses feedback inhibition 
of NE release. This phenomena results in depletion of cytoplasmic pre-
synaptic NE levels. In chronically treated protriptyline animals constant 
exposure to NE in the synapse results in the evolution of a state of 
subsensitivity of both pre- and post-synaptic receptors. In other words, 
receptor tolerance develops as a result of constant NE exposure. 
Constant exposure to elevated synaptic concentrations of NE 
produces receptor subsensitivity in a time course which parallels the 
observed lag-time for clinical efficacy for this class of antidepressant 
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agents. Post-synaptic receptor subsensitivity has already been documented 
in peripheral systems (Langer and Luchelli-Fortis, 1977). 
B. SUMMARY 
We have documented several compensatory neural mechanisms which 
occur during the chronic treatment period with tricyclics: (1) changes 
in endogeneous cytoplasmic total NE levels, (2) changes in NE turnover 
rate/recovery rate following the last dose in a chronic series of test 
drug administrations, and (3) adaptations in the pre-synaptic receptor. 
1. Adaptations in total NE tissue levels. 
Decreases in cytoplasmic NE levels following chronic protriptyline 
treatment (Figure 7) suggest a more efficient utilization of NE (less 
neurotransmitter is required to maintain normal physiologic function). 
Clinical studies support this postulate and report increases in H3-NMN 
(a COMT metabolite) and decreases in H3-DCM (MAO metabolies, 3, 4-
dihydroxymandelic acid and 3, 4-dihydroxy-phenyl-glycol) following 
chronic tricyclic administration. These data indicate that more neuro-
transmitter is available to synaptic receptors (and COMT), despite an 
observed reduction in total endogeneous cytoplasmic NE levels. 
2. Adaptations in NE turnover. 
Acute protriptyline administration results in a decreased slope 
for NE turnover~ three and six hours after tricyclic administration, when 
compared to saline treated animals. Twenty-four hours after protriptyline 
administration the slope for NE turnover has returned to control values 
(T~bles 6 and 7). This observation has been observed by others when 
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measuring H3-metabolites (H3-NMN) following H3-NE infusion, and employing 
acutely imipramine or DMI pretreatment. Since re-uptake blockade by 
tricyclics results in an accumulation of NE in the synapse, this 
accumulation would stimulate pre-synaptic alpha-receptors and in turn 
a negative feedback mechanism would become operative; thus resulting in 
a decrease in the release of pre-synaptic NE.. This mechanism is re-
sponsible for the decrease in NE turnover following acute protriptyline 
administration. 
With subchronic (6 day) protriptyline treatmer.t, the slope for NE 
turnover appears to be elevated at both the three and six hour time 
points after the last protriptyline injection, when these slopes for 
turnover rate are compared to the turnover rates for acute protriptyline 
administration. Similarly, the slopes for turnover rate for chronically 
administered animals also suggest an increase in NE turnover rate, when 
compared to acute protriptyline administration. These data suggest the 
development of receptor adaptations following a chronic tricyclic 
treatment schedule. 
Figure 18, a turnover rate/recovery rate plot, depicts this 
comparison of turnover slopes for acute, subchronic and chronic treatment 
groups. This figure explicitly demonstrates the modifications in 
neurotransmitter turnover rate/recovery rate in the three treatment 
sehedules. 
3. Adaptations in pre-synaptic receptor sensitivity. 
Pre-synaptic alpha-receptor adaptation (hyposensitivity) following 
chronic protriptyline administration is suggested by our data. Since 
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yohimbine prevents pre-synaptic alpha-receptor stimulation, and allows 
NE overflow to the adrenergic synapse to occur, chronic protriptyline 
administration modifies this mechanism. Control of NE release by these 
receptors (which is dependent upon synaptic NE concentration) is al-
tered, thus the negative feedback mechanism for facilitating or suppress-
ing the controlled release of NE to the synapse becomes modified. 
When animals were administered protriptyline chronically and 
subsequently administered yohimbine, a decrease in endogeneous NE levels 
was not observed in our studies (Figure 17). These results are contrary 
to earlier studies involving yohimbine administration to control animals 
(Figure 15). This observation suggests that chronic protriptyline 
administration induces pre-synaptic hyposensitiivity. 
C. CONCLUSIONS 
It appears that chronic protriptyline administration results in 
adaptive changes in central noradrenergic mechanisms. The time course 
for these adaptive changes parallel the time required for the onset 
of their clinical effectiveness. We propose that acutely the action of 
tricyclics on norepinephrine re-uptake is {largely) negated by com-
pensatory adjustments in turnover rate of the neurotransmitter; but 
with chronic administration, adaptations in pre-synaptic alpha-receptors 
occur. This in turn reduces the extent to which the norepinephrine 
neurons can offset or compensate for the blockade of norepinephrine re-
uptake. Specifically, pre-synaptic alpha-receptors become hyposensitive, 
and tolerance develops, not to the direct action of the tricyclic drug 
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on neurotransmitter re-uptake, but to the compensatory neural adjustments 
which offset the action of the acute tricyclic administration and delay 
their clinical efficacy. 
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C H A P T E R VII 
(Appendix Section) 
TABLE 1 Kinetic parameters for monoamine oxidase activity in three brain regions 
Km (x io-6 M) Vmax (mnoles of 5-HIAA or 
IAA formed/hr.ug DNA) 
TISSUE 5-HT (r2) tryptamine (r2) 5.-HT tryptamine 
Corpus Striatum 28 .o 0.9961 9.0 0.9988 0.2389 1.1362 
Forebrain 45.0 0.9988 12.0 0.9994 0. 7759 3 .0816 
Hypothalamus 27.0 o. 9975 9.0 0. 9989 0.3467 1.5766 
N = 6 
Km and Vmzx values were calculated following linear regression analysis. 
... 
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TABLE 3.0 The effect of acute protriptyline administration (one 
injection) on MAO activity in three rat brain regions1 
Time sacrificed 
after drug 
administration 
(hours) 
Protriptyline Group Saline group2 
14 C -tryptamine(IAA) 
2.103 + 0.3663 
2.657 + 0.276 
2 .800 + 0 .454 
2.569 + 0.147 
2.275 + 0.165 
3.002 + 0.184 
2.657 + 0.276 
4.166 + 0.670 
3.151 + 0.246 
3.365 + 0.566 
2.029 + 0.201 
2 .238 + 0.309 
2.196 + 0.266 
2.181 + 0.189 
l.401 +0.205 
Corpus Striatum 
Forebrain 
Hypothalamus 
cl4-serotonin(5-HIAA) 
Corpus Striatl.D'll 
Forebrain 
Hypothalamus 
l 
3 
6 
12 
24 
l 
3 
6 
12 
24 
l 
3 
6 
12 
24 
l 
3 
6 
12 
24 
l 
3 
6 
12 
24 
l 
3 
6 
12 
24 
0.287 + 0.041 
0.539 + 0.058 
0.426 + 0.052 
0.370 + 0.017 
0.452 + 0.041 
0.416 + 0.029 
0.535 + 0.046 
0.665 + 0.135 
0.459 + 0.048 
0.664 + 0.098 
0.224 + 0.040 
0.423 + 0.088 
0.308 + 0.030 
0. 264 + 0. 031 
0.245 + 0.026 
l.969 + 0.345 
2.702 + 0.624 
2 .888 + 0.201 
2.262 + 0.126 
2.428 +o.145 
2.425 +o.370 
2.702 + 0.624 
4.862 + 0.831 
2 .837 + 0 .109 
2.436 + 0.110 
l.950 + 0.331 
2.330 + 0.173 
2.059 + 0.268 
l. 927 + 0 .168 
l. 678 + 0 .152 
0.273 + 0.046 
0 .443 + 0 .068 
0.465 + 0.055 
0 • 3 2 5 + 0 • 0 27 
0.455 + 0.032 
0.409 + 0.052 
o.547 + 0.058 
0.850 + 0.014 
0 .408 + 0 .014 
0.457 + 0.036 
0.228 + 0.028 
0.398 + 0.063 
0.284 + 0.025 
0.217 + 0.021 
0.306 + 0.059 
lProtriptyline administration (10 mg/kg/day) subcutaneous injection 
2Equal volumes of saline were administered to controls 
3N = 6 for all groups, values represent the Hean + S.E.H. for HAO 
activity and are reported as nanomoles of 5-HIAA-or IAA formed/hr./ 
ug DNA 
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TABLE 4.0 The effect of subchronic protriptyline administration (three 
consecutive injections) on MAO activity in three rat brain 
regionsl · 
c
14
-tryptamine 
Corpus Stria tum 
Forebrain 
Hypothalamus 
c14-serotonin 
Corpus Striatum 
Forebrain 
Hypothalamus 
Time sacrificed 
after last drug 
administration 
(hours) 
3 
6 
12 
24 
3 
6 
12 
24 
3 
6 
12 
24 
3 
6 
12 
24 
3 
6 
12 
24 
3 
6 
12 
24 
Protriptyline 
Group 
2.429 + 0.2353 
1.775:; 0.150 
1.861 :; 0 .196 
2 • 3 27 + 0 • 2 27 
2.841 + 0.209 
2.824 +0.204 
3.111 + 0.203 
3.261 :; 0.150 
2.487 + 0.198 
1.880 + 0.125 
2.025 :; 0.308 
2.358 +0.102 
0.568 + 0.035 
0.402 :; 0.026 
0.402 + 0.045 
0.502 :; 0.031 
0.618 + 0.053 
0.622 :; 0.050 
0.600 :; 0.033 
0.681:; 0.036 
0.598 + 0.053 
0.428 :; 0.036 
0 .359 + 0 .047 
0.453 + 0.022 
Saline Group2 
2.352 + 0.112 
l. 711 :; 0 .190 
2.262:; 0.146 
2.027 :; 0.205 
2.647 + 0.094 
2.662:; 0.151 
3.337 + 0.237 
2.893 +0.203 
2.102 + 0.298 
l.493 +o.345 
2 .078 :; 0 .348 
1.937 + 0.101 
0.512 + 0 .027 
0. 38 5 + 0. 04 3 
0.437 :; 0.021 
0.495 :; 0.032 
0.507 + 0.016 
0.610 :; 0.027 
0.674 :; 0.059 
0.669 + 0.058 
0.424 + 0.038* 
0.355:; 0.060 
0 • 5 7 3 + 0 • 07 9* 
0.442 :; 0.018 
lProtriptyline administration (10 mg/kg) subcutaneous injection 
2Equal volumes of saline were administered to controls 
3N = 6 for all groups, values represent the Mean + S.E.M. for HAO 
activity and are reported as nanomoles of 5-HIAA-or IAA formed/hr./ 
ug DNA 
*p <. o.os from protriptyline group 
TABLE 5.0 The effect of subchronic protriptyline administration (six 
consecutive injections) on MAO activity in three rat brain 
regionsl 
c14-tryptamine 
Corpus Striatum 
Forebrain 
Hypothalamus 
cl4-serotonin 
Corpus Striatum 
Forebrain 
Hypothalamus 
Time sacrificed 
after last drug 
administration 
(hours) 
3 
6 
12 
24 
3 
6 
12 
24 
3 
6 
12 
24 
3 
6 
12 
24 
3 
6 
12 
24 
3 
6 
12 
24 
Protriptyline 
Group 
2.359 + 0.1753 
2.326 + 0.170 
l.995 + 0.093 
2.132 + 0.262 
3.304 + 0.407 
3. 505 + 0. 261 
4 .808 + 0 .446 
2.411 +0.191 
1.791 + 0.032 
l.659 + 0 .101 
2.798 +o.164 
l.903 + 0.177 
0.519 + 0.059 
0.589 + 0.049 
0.388 + 0.029 
0.238 + 0.039 
0.669 + 0.061 
0 .815 + 0 .073 
0.938 + 0.080 
0.292 + 0.036 
0.395 + 0.017 
0.394 + 0.025 
0.478 + 0.033 
0.207 + 0.030 
Saline Group2 
2 • 3 27 + 0 • 24 0 
2 .173 + 0 .153 
2.697 +o.218* 
2.616 +o.288 
3.431 + 0.264 
2.923 + 0.219 
3 .106 + 0 .147;': 
3.922 + 0.743 
2.101 + 0.145 
l.839 + 0 .180 
2.061 +o.256* 
2.127 +0.211 
0.512 + 0.055 
0.461 + 0.049 
0.426 + 0.050* 
0•374 + 0.033;': 
0.669 + 0.048 
0.599 + 0.052i: 
0.672 + 0.037* 
0.619 + 0.108* 
0.433 + 0.026 
0.429 + 0.073 
0.454 + 0.059* 
0.259 + 0.040 
lProtriptyline administration (10 mg/kg) subcutaneous injection 
2Equal volumes of saline were administered to controls 
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3N = 6 or more animals for all groups examined; values represent the 
MEAN !. S.E.M. for HAO activity and are reported as nanomoles of 
5-HIAA or IAA formed/hr./ug DNA 
*P ~0.05 from protriptyline group 
142 
TABLE 6.0 The effect of chronic protriptyline administration (18 
consecutive injections) on MAO activity in three rat brain 
regionsl 
Time sacrificed Protriptyline Saline Group2 
after last drug Group 
administration 
c14-tryptamine 
(hours) 
3.792 + 0.3303 Corpus Striatum 3 2.553 + 0.262* 
6 2.965 + 0.778 l.861 + 0.094 
12 2.576 + 0.212 2.743 +0.275 
24 l. 792 + 0 .147 1.939 + 0.131 
Forebrain 3 3.338 + 0.183 3.256 + 0.167 
6 3 • 2 54 + 0 .17 4 3 .373 + 0 .137 
12 3.339 + 0.305 3.261 + 0.181 
24 3.273+0.226 2 .894 + 0 .057 
Hypothalamus 3 2 • 7 04 + 0 • 3 9 0 2 • 4 5 2 + 0 .197 
6 2.441 + o.327 2.069 + 0.154 
12 2 .376 + 0 .118 2.319 + 0.090 
24 2.183 + 0.130 2.279 + 0.142 
cl4-serotonin 
Corpus Striatum 3 0.752 + 0.077 0.512 + 0.047* 
6 0 .688 + 0 .192 0.447 + 0.056 
12 0.631 + 0.038 0.685 + 0.045 
24 0.423 + 0.044 0.453 + 0.020 
Forebrain 3 o.739 + 0.042 0.826 + 0.088 
6 0.709 + 0.045 0.686 + 0.037 
12 0 • 97 5 + 0 • 07 4 0.851 + 0.065 
24 0.720 + 0.031 0.676 + 0.028 
Hypothalamus 3 0.495 + 0.084 o.513 + o.o5a 
6 0.456 + 0.054 0.416 + 0.032 
12 o.551 + 0.023 0.545 + 0.030 
24 0.454 + 0.047 0.355 + 0.036 
lProtriptyline administration (10 mg/kg) subcutaneous injection 
2Equal •olumes of saline were administered to saline rats to serve 
as controls 
3N = 6 for all determinations; values represent the Mean + S.E.M. 
for MAO activity and are reported as nanomoles of 5-HIAA-or IAA 
formed/hr./ug DNA 
*p~ 0.05 fraa protriptyline group 
FIGURE 1 
TITLE: Velocity versus substrate concentration for MAO 
activity in the corpus striatum 
LEGEND 
14J 
Monoamine oxidase activity in the corpus striatum has been evaluated 
using Michalis-Menton kinetics and employing c14-tryptamine as 
substrate. MAO enzyme activity begins to pla~eau at 20.0 x 10-6 M 
substrate concentration. Each point represents the MEAN of 6 
experimental determinations. Similar results were obtained when 
forebrain or hypothalamus were examined and c14-tryptamine was 
employed as substrate. Numerical values for all enzyme velocity 
versus substrate concentration are listed in the appendix section 
(Tables 19-26). 
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FIGURE 2 
TITLE: Reciprocal plot for HAO enzyme velocity versus substrate 
concentration (Lineweaver-Burke) 
LEGEND 
This graph represents a reciprocal plot of the data obtained in 
Figure l. The Km value for MAO is 9.0 x lo-6~, which agrees 
with the values reported by Collins, (1972) and Tipton, (1972) 
in pig brain, rat liver and beef adrenal medulla. Similarly, 
the Vmax value obtained is 1.1362 nmoles of IAA formed/hr/ug DNA. 
The linear regression coefficient Cr 2) is 0.9988. 
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FIGURE 3 
TITLE: Velocity versus substrate concentration for MAO activity 
in corpus striatum. 
LEGEND 
Monoamine oxidase activity in the corpus striatum has been 
evaluated using Hichalis-Henton kinetics and employing c14-
serotonin as substrate. MAO enzyme activity begins to plateau at 
20.0 x 10-6 H substrate concentration. Each point represents 
the HEAN of 6 experimental determinations. Similar results 
were obtained when forebrain o~ hypothalamus were examined and 
cl4-serotonin was employed as substrate. Numerical values for 
all enzyme versus substrate concentration are listed in the 
appendix section (Tables 19-26). 
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FIGURE 4 
TITLE: Reciprocal plot for MAO enzyme velocity versus 
substrate concentration (Lineweaver-Burke) 
LEGEND 
This graph represents a reciprocal plot of the data obtained in 
Figure 3. The Km value for MAO, when cl4 -serotonin has been 
employed as substrate, is 28.0 x lo-6M. This value is in 
agreement with other investigators (Collins, 1972; Tipton, 
1972; Fowler and Oreland, 1979; Suzuki, 1979). Similarly, 
the Vmax value obtained is 0.2389 nmoles of 5-HIAA formed/hr/ 
ug DNA. The linear regression coefficient Cr 2) is 0.9961. 
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FIGURE 5 
TITLE: Monoamine oxidase activity in corpus striatum following 
LEGEND 
in vitro preincubation with varyin~ molar concentrations of 
protriptyline. 
MAO activity has been evaluated in the corpus striatum following 
preincubation with protriptyline. cl4 -tryptamine has been used as 
the substrate. Each data point represents the MEAN + S.E.M. for 
6 experimental determinations. Inhibition of MAO activity begins 
at a molar concentration of protriptyline at lo-5 M. 
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FIGURE 6 
TITLE: 
LEGEND 
153 
Monoamine oxidase activity in corpus striatum following 
in vitro preincubation with varying molar concentrations 
of protriptyline. 
MAO activity has been evaluated in the corpus striatum following 
preincubation with protriptyline. cl4-serotonin has been used as 
the substrate. Each data point represents the MEAN + S.E.M. for 
6 experimental determinations. Inhibition of MAO activity begins 
at a molar concentration of protriptyline at io-5 M. 
0.70 
..::t 
l(\ 
... 
0 .6~ ~ 
I 
.-( a.so 
z 
0 
CSl 
2-
0.4 a: :c 
-0 
~ 
a: 
0 
u.. 
< 
< 
..... 
Ill 
UJ 
_. 
0.20 0 ~ 
0.10 
(10 l ·11 . '-fQ -9 -6 -7 -6 -5 -4 I -J 
protriptylin• 10 10 10 10 10 10 10 10 10 
!i CONCENTRATION OF PROTRIPTYLINE 
TABLE 11 The effect of thyroidectomy and acute 
protriptyline on MAO activity in three 
brain regions. 
Saline Acute 
and Sham Tx and Protriptyline 
Time Control Saline and Tx 
Tryptamine 
cs 1 2 .83 + .17 3.30 + .38 2.18 + .31* 
3 2.75 + .16 2.32 + .25 2.10 + .13+ 
6 2. 77 .19 2.98 + .14 2.27 - .13+ + + 
12 3.13 .45 2.12 + .24 3.24 - .35 + + 
24 2. 72 + .15 1.90 + .OB** 1.98 - .OB** + 
r 1 3 .53 + .21 3. 75 + .29 3.97 + .40 
3 3.50 + .20 3.08 + .16* -2.84 + .15 
6 3.85 + .25 4.18 + .30 3 .19 + .24 
12 3.11 + .26 2.61 + .14 3.08 + .40 
24 3.87 + .37 2.61 -+ .14* 2.29 + .12** 
Hy 1 2.63 + .39 3.04 + .33 2.27 + .22 
3 2.52 + .36 2.60 + .23 1.77 - .16+ + 
6 2.04 + .42 2 .81 + .19 3.03 - .17 + 
12 5.35 + .as 1.81 - .12** 2.63 - .1s+• + + 
24 3.70 + • 72 1.81 + .12• 1.97 + .32* 
Serotonin 
cs 1 0.67 + .os o. 76 + .11 0.61 + .04 
3 0.64 + .05 a.so + .os 0.48 + .03 
6 0.81 + .09 0.69 + .03 0.56 + .02++* 
12 0.83 + .11 0.40 + .03** 0.62 + .oa+• 
24 0.51 + .03 0.32 + .03** 0.34 + • Q2Mt 
r 1 o.76 + .05 0.78 + .08 o.91 + .10 
3 0.75 + .05 0.62 + .04* 0.60 + .04 
6 0.83 + .04 0.82 + .03 0.70 + .os 
12 0.75 + .07 0.53 + .02* o.59 + .09 
24 0.71 + .07 0.53 + .02 0.41 + .03+•• 
Hy 1 0.65 + .06 0.64 + .oa 0.53 + .05 
3 0.61 + .os 0.48 + .03 0.46 + .02• 
6 0.50 + .09 0.56 + .04 0.69 + .04 
12 1.17 + .12 0.27 + .02•• 0.43 + .03+•• 
24 0.69 + .15 0.27 + .02* 0.27 + .04* 
N = 6 per group 
* 
Significantly different than control p~ .05 
** 
Significantly different than control p" .01 
+ Significantly different than Tx and Saline p ~ • 05 
++ Significantly different than Tx and Saline p c • 01 
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TABLE 12 The eff ec:t of thyroidectomy and three days 
protriptyline on MAO activity in three brain 
regions. 
Sham Thyroidectomized 
Operated Thyroidectomized and 
Time and Saline and Saline Protriptyline 
Tr~Etamine 
cs 
F 
H 
Serotonin 
cs 
F 
H 
· 3 1.71 + .18 2.09 + .18 2.48 + .15** 
6 2.42 + .15 2 .38 + - .22 .20 2.28 + 
12 2.35 + .12 3.20 + .36* -2.30 + .16 
24 2.38 + • 35 2 .49 + .20 2.14 + .08 
3 3.21 + .23 2.9S + .14 2 .as + .16 
6 3.07 + .25 4 · .. 06 + .57 6.28 +l.29 
12 2.64 + .10 3.09 + -.2s 3.17 + 
24 2.96 + .15 3 .34 + .38 2.98 + 
3 1.70 + .10 2.19 + .27 2.23 + 
6 2.76 + .32 2.12 + .16 2.19 + 
12 2.12 + .29 3,'32 + .23** 2.38 -+ 
24 2.2s + .25 2.7S - .24* 2.02 -+ + 
3 O.Sl + .05 0.46 + ,04 0.54 + 
6 0.65 - .06 0.56 + .07 0.57 -+ + 
12 0.52 + .03 0.75 + .09* 0,64 + 
24 0.62 - .10 0.49 + .06 0.46 -+ + 
3 0,98 + .06 0.62 + .03R* o.5a + 
6 0.92 + .07 1.09 + .18 l.46 + 
12 0.53 + .02 0.68 + .07* 0.69 + 
24 0.70 + .08 0.73 + .10 0.64 + 
3 0.50 + .os 0.50 + .06 0.40 + 
o.79 + .09 0.55 + .09 0.47 -6 + 
12 0.43 + .04 0.69 + .04** 0.67 + 
2~ 0.54 + .05 0.52 + .04 0 .40 + 
N = 6 per group 
• Significantly different than control p ,.os 
** Significantly different than control p ~ .01 
.09*" 
.25 
.21 
.13 
.36++ 
.1a++ 
.OS 
.06 
.04* 
.01 
.03** 
.36 
.03** 
.05 
.03 
.03•+ 
.11* 
.03•++ 
+ Significantly different than thyroidectomized-saline p~.05 
++ Significantly different than thyroidectomized-saline p ~.01 
' , 
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TABLE 13 The effect of thyroidectany and six days 
protriptyline on MAO activity in three brain 
regions. 
Sham Thyroidectomized 
Operated Thyroidectomized and 
Tryptamine 
cs 
F 
H 
Serotonin 
cs 
r 
H 
N = 
** 
+ 
Time and Saline 
3 2.33 + .23 
6 2 .BB + .15 
12 2.05 + .14 
24 3.3B + .37 
3 3.43 + . • 27 
6 3.09 + .09 
12 2.97 + .16 
24 3.94 + .44 
3 2.11 + .15 
6 2.57 + .31 
-12 2.25 + .25 
-24 2.37 + • 24 
3 O.S2 + .05 
6 0.66 + .os 
12 0.54 + .os 
24 0.60 + .05 
3 o. 75 + .06 
6 0.10 + .06 
i2 o. 70 + .07 
24 l.03 + .20 
3 0.44 + .03 
6 0.59 + .07 
12 0.53 + .05 
24 0.3B + .04 
6 per group 
Significantly different 
Significantly different 
Significantly different 
++ Significantly different 
and Saline Protriptyline 
2.0B + .12 2.13 + 
l.68 + .16** l.77 + 
2.41 + .lB l.Bl + 
2.59 + .31 2.90 + 
3.09 + .16* 3 .21 + 
2.19 + .37 2.B9 + 
2 .62 + .15 2.60 + 
5 .05 + .51 3.22 -+ 
l.B9 + .10 l.B6 + 
1.67 + .14* 2.26 + 
2 .40 + .lS l.64 -+ 
2 .09 + .2s 2.09 -+ 
0.52 + .04 0.69 + 
0.57 + .05 0.55 -+ 
0.79 + .OS* 0.54 -+ 
o.so + .05 o.so -+ 
0.6B + .06* O.B3 + 
0.94 + .14* o.B7 + 
-o. 79 + .04 0.69 + 
l.03 + .10 0.5B + 
0.46 + .04 0 .5B + 
0.46 + .07 0.61 -+ 
0.73 + .04** 0.42 + 
0.33 - .06 0.40 + + 
than control p ( .05 
than control p ~ • 01 
.19 
.OB** 
.24 
.lB 
.lB 
.17 
.16 
.23++ 
.22 
.26 
.l4il++ 
.lB 
.04*++ 
.03* 
.06+ 
.OS 
.07 
.07* 
.04 
.05++ 
.04**+ 
.07 
.04*++ 
.04 
than thyroidectomized-saline p4 .os 
than thyroidectomized-saline p" • 01 
TABLE 14 Kinetic Parameters for HonOaJ1ine Oxidase 
Activity in Three Brain Regions 
Corpus Striatum: using c14-trypt&mine as Substrate 
l/Vmax : 0.880116 l/Km = 1.15749 x 105 
Vsax : 1.136213 Km : 9.0 x 10-6 M 
R2 = 0.9988 slope = 0.000008 
using c14-serotonin as Substrate 
l/Vmax = 4.18507 lKm = 3 .607329 x 10
4 
Vmax = 0.23895 Km = 28.0 x 10-6 H 
R2 = 0.9961 slope = 0.000116 
Forebrain: using c14-tryptamine as Substrate 
l/Vmax = 0.324503 l/Km = 8 .18113 x 104 
Vmax = 3.08164 Km = 12.o x 10-6 M 
R2 = 0.9994 slope = 0.000004 
i c14 • us ng -serotonin as Substrate 
l/Vmax = 1.2887 l/Km = 2.2044 x 104 
Vll&X : 0 • 77 5 9 = 24.0 x 10-6 M 
= 0.9988 slope = 0.0001 
Hypothalamus: u.sing c14-tryptamine as Substrate 
l/Vmax = 0.63429 l/l<m = 1.1684 x 10
5 
Vmax = l.576561 Km = 9.o x lo-
6 M 
R2 = 0.99897 slope = o.oooos 
using c14-aerotonin as Substrate 
l/Vmax = 2.88438 l/Knl = 3.6383 x 104 
Vmax = 0.346695 l<m • 21 .o x 10-6 M 
R2 = 0.99753 slope = 0.000079 
N=6 for all determinations using linear regression analysis 
158 
MEAN 
S.E.H. 
TABLE 15 Richalis-Menton Data for Corpus Striatwn 
using cl4-tryptamine as Substrate (Y vs S) 
2.0 s.o 10.0 20.0 30.0 Substrate Cone. c10-6 H> 
cl4 -tryptamine 
0.290 0.543 0.811 1.124 l.163 
0.01 0.12 0.17 0.23 0.24 
N=6 Values represent the Mean + S.E.M. for nmoles of 5-HIAA 
formed/hr./ug DNA 
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TABLE 16 Lineweaver-Burke Data for Corpus Striatwa 
using cl4-tryptamine as Substrate (l/V vs l/S) 
33.3 50.0 100.0 200.0 500.0 ( x 103) 
MEAN 4.677 2.411 1.674 1.175 1.180 
S.E.H. l.12 0.54 0.44 0.29 0.34 
30.0 20.0 10.0 s.o 2.0 (Substrate Cone. l0-6 M) 
cl4_tryptuine 
N=6 Values represent the Mean + S.E.M. for nanomoles of 5-HIAA 
formed/Wug DMA 
MEAN 
S.E.H. 
TABLE 17 Michalis-Menton Data for Corpus Striatum 
using cl4_aerotonin as Substrate (V vs S) 
2.0 s.o 10.0 20.0 30.0 Substrate Cone. uo-6H> 
cl4-serotonin 
0.033 0.069 0.129 0.183 0.205 
0.01 0.02 0.04 0.01 0.10 
N=6 Values represent the Mean + S.E.M. for nmoles of IAA 
formed/hr./ug DNA 
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TABLE 18 Lineweaver-Burke Data for Corpus Striatum 
using cl4-serotonin as Substrate (l/V vs l/S) 
33.3 50.0 100.0 200.0 soo.o ( x 103) 
MEAN 61.957 28.267 14.761 11.895 6.521 
S.E.M. 24.06 10.65 5.08 S.27 2.50 
30.0 20.0 10.0 s.o 2.0 (Substrate Cone. io-6M) 
cl4_serotonin 
N=6 Values represent the Mean + S.E.M. for moles of IAA 
formed /hr. /ug DNA 
2.0 
TABLE 19 Michalis-Menton Data far Farebrain 
5.0 
using cl4_tryptamine as Substrate (V vs S) 
10.0 20.0 30.0 Substrate Cone. (10-6H) 
cl4_tryptamine 
161 
MEAN 0.466 0.936 l.417 2.057 2.333 
S.E.H. 0.06 0.12 0.12 0.23 0.22 
MEAN 
S.E.M. 
N=6 Values represent the Hean + S.E.H. for nmoles of 5-HIAA 
formed /hr. /ug DNA 
TABLE 20 Lineweaver-Burked 
C14-tryptamine as 
33.3 50.0 100.0 200.0 500.0 
2.297 1.148 0.726 0.510 0.445 
0.25 0.13 0.05 0.05 0.04 
30.0 20.0 10.0 5.0 2.0 
Data for Forebrain using 
Substrate (l/V vs l/S) 
( x 103) 
(Substrate Cone. lo-6M) 
cl4_tryptamine 
N=6 Values represent the Mean + for nanomoles of 5-HIAA 
formed/hr./ug DNA 
' . 
MEAN 
S.E.H. 
MF.AN 
S.E.H. 
TABLE 21 Michalis-Menton Data for Forebrain using 
cl4_99r0tonin as Substrate (V VS S) 
2.0 s.o 10.0 20.0 30.0 Substrate Cone. (10-6M) 
cl4_serotonin 
0.445 0.109 0.189 0.288 0.365 
0.01 0.02 0.04 0.04 0.04 
N=6 Values represent the Mean + S.£.M. for IDoles of IAA 
formed/hr./ug DNA 
TABLE 22 Lineweaver-Burke 
cl4-serotonin as 
33.3 50.0 100.0 200.0 500.0 
30.327 13.367 7 .572 4.000 2 .817 
4.34 1.46 0.91 0.39 0.25 
30.0 20.0 10.0 s.o 2.0 
Data for Forebrain using 
Substrate (l/V VS l/S) 
( x 103 ) 
(Substrate Cone. io-6M) 
cl4-serotonin 
162 
N=6 Values represent the Mean + S.E.M. for nananoles of IAA 
formed/hr. ug DNA 
MEAN 
S.E.M. 
MEAN 
S.E.M. 
2.0 
0.334 
a.as 
N=6 
TABLE 23 Micbalis-Menton Data far Hypothalamus using 
cl4_tryptamine as Substrate (V vs S) 
5.0 10.0 20.0 30.0 Substrate Cone. uo-6M> 
cl4_tryptamine 
0.617 0.9Sl 1.299 l.Sll 
0.01 0.15 0.19 0.23 
163 
Values represent the Mean + S.E.M. for nanomoles of 5-HIAA 
formed /hr • /ug DNA 
TABLE 24 Lineweaver-Burke Data for Hypothalamus using 
cl4-tryptamine as Substrate (l/V vs l/S) 
33.3 so.a 100.0 200.0 500.0 (x 103) 
3.329 1.770 1.196 0.878 o.793 
0.4S 0.25 0.19 0.16 0.18 
30.0 20.0 10.0 s.o 2.0 (Substrate Cone. io-6H) 
cl4-tryptamine 
N=6 Values represent the Hean + S.E.M. for nmoles of S-HIAA 
formed/hr./ug DNA 
MEAN 
S.E.M. 
MEAN 
S.E.M. 
2.0 
0.027 
0.01 
N=6 
TABLE 25 Michalis-Henton Data for Hypothalamus using 
cl4_aerotonin as Substrate (V vs S) 
s.o 10.0 20.0 30.0 Substrate Cone • (lo-6M) 
cl4-serotonin 
0.060 0.107 0.171 0.185 
0.02 0.02 0.04 0.02 
Values represent the Hean + S.E.M. for nnoles of IAA 
formed/hr./ug DNA 
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TABLE 26 Lineweaver-Burke Data for Hypothalamus using 
cl4-serotonin as Substrate (l/V vs l/S) 
33.3 so.o 100.0 200.0 
42.068 19.947 ll.061 6.535 
5.95 3.64 l.71 l.10 
30.0 20.0 10.0 s.o 
soo.o 
4 .838 
0.66 
2.0 
(x 103) 
(Substrate Cone. 10-6H) 
cl4 -serotonin 
N=6 Values represent the Mean + S.E.M. far nanomoles of IM 
formed/hr./ug DNA -
TABLE 27 In Vitro Monoaaine Oxidase Activity following Preincubation with varying molar concentrations of 
Protriptyline (Preincubation - 30 minutes at 40 C) 
No 
Corpus Striatua Protriptyline 10-11 
-
10-10 lo-9 lo-8 lo-7 lo-6 lo-5 lo-4 lo-3 M. 
MEAN 2.135 2 .085 2.024 2.020 2.000 1.977 2.009 1.825 1.591 0.447 
S.D. 1.067 1.063 1.120 1.127 1.149 0.996 1.032 0.933 0.978 0.323 
S.E.M. 0.435 0.434 0.457 0.460 0.469 0.398 0.421 0.381 0.399 0.132 
Forebrain 
MF.AN 13.005 11.955 11.902 11.412 11.478 11.548 11.281 11.026 10.370 3.423 
S.D. 2.931 2.538 2.563 2.395 2.184 2.245 2.139 2.211 2.120 o.704 
S.E.M. 1.197 1.032 1.046 0.978 0.89.l 0.917 o.874 0•903 0.866 0.288 
Hypothalamus 
MF.AN 1.678 1.599 1.536 1.476 1.578 1.523 1.506 1.379 1.162 o.278 
S.D. 0.681 0.649 0.590 0.598 0.678 0.635 0.668 0.579 0.492 0.166 
S.E.M. 0.278 0.265 0.241 0 .244 . 0.277 0.259 0.273 0.236 0.201 0.068 
Nc6 for each determination 
Values represent the nanomoles of 5-HIAA for11ed/hr./ug DNA 
Monoamine Oxidase substrate used in this experiment was c14-tryptamine ~ 
0\ 
\Jl 
TABLE 28 In Vitro Monoamine Oxidase Activity following Preincubation with varying aolar concentrations of 
Protriptyline (Preincubation - 30 minutes at 4o C) 
Ho 
Corpua Striatum Protriptyline 10-11 l0-10 l0-9 l0-8 l0-7 lo-6 io-5 lo-4 lo-3 M. 
-
MEAN 0.591 0.556 0.562 o.514 0.516 0.518 0.503 0.478 0.352 0.011 
S.D. 0.392 0.385 0.359 o.344 0.365 0.392 0.335 0.347 0.234 0.022 
S.E.M. 0.160 0.157 0.146 0.141 0.149 0.160 0.137 0.1142 0.095 0.009 
Forebl'ain 
MEAN 3.530 3.291 3.291 3.289 3.230 3.280 3.200 2.9143 2.2114 0.221 
S.D. 0.813 0.631 0.716 0.671 o.736 o.746 0.803 0.874 0.1440 0.052 
S.E.M. 0.332 0.258 0.292 0.274 0.300 0.304 0.328 0.357 0.180 0.021 
Hypothalamus 
MEAN 0.14314 0.390 0.371 0.1400 0.1411 0.382 0.367 0.3147 0.210 0.009 
s.o. 0.213 0.192 0.161 0.181 0.211 0.195 0.203 0.183 0.109 0.010 
S.E.M. 0.087 0.978 0.066 0.9714 0.086 0.080 0.083 0.075 0.0145 0.0014 
N•6 for each determination 
Values represent the nanomoles of IAA formed/hr./ug DNA 
Monoamine Oxidase substrate used in this experiment was cl14-serotonin _. 
0\ 
0\ 
TABLE 29 MAO Activity following preincubation with various molar concentrations of T3 and for various 
preincubation tiJlle intervals 
Molar Concentration 
of T3 
No T3 
lo-9M 
l0-7M 
10-SM 
10-ltM 
l0-3M 
No Preincubation 
0.480 + 0.01 
o.320 + 0.01 
o.334 + 0.01 
0.263 + o.os 
0.194 + 0.03 
-
0.084 + 0.02 
N=3 for each determination 
Corpus Striatum 
Preincubation Times (Minutes) 
15 minutes 30 minutes 60 minutes 
0.359 + 0.04 O.lt03 + 0.03 0.427 + 0.04 
-
0.292 + 0.07 0.302 + o.os 0.266 + 0.01 
-
0.334 + 0.13 0.322 + 0.09 0.259 + 0.09 
- -
o.317 + 0.12 0.324 + 0.06 0.288 + 0.09 
- -
0.218 + 0.03 0.167 + 0.02 0.184 + 0.03 
- -
0.100 + 0.02 0.069 + 0.03 0.065 + 0.01 
Values represent the Mean .:!:. S.E.M., and are reported as nanomoles IAA formed/hr./ug DNA 
Substrate employed was cllt_serotonin 
_. 
0\ 
-J 
TABLE 30 MAO Activity following preincubatlon with various molar concentrations of T3 and for various 
preincubation time intervals 
Molar Concentration 
of T3 
No r 3 
l0-9H 
io-7M 
l0-5M 
l0-4M 
io-3M 
No Preincubation 
0.546 + 0.05 
-
0.399 + 0.01 
-
0.408 + 0.02 
0.352 + 0.04 
-
0.278 + 0.01 
0.177 + 0.04 
N•3 for each determination 
Forebrain 
Preincubation Times (Minutes) 
15 minutes 30 minutes · 60 minutes 
0.551 + ·0.02 o.539 + o.o3 0.523 + 0.01 
-
0.397 + 0.05 0.397 + 0.05 0.384 + 0.06 
- - -
0.419 + 0.01 0.424 + 0.01 0.405 + 0.06 
0.404 + 0.05 0.435 + 0.04 0.376 + 0.04 
-
0.302 + 0.05 0.291 + 0.03 0.254 + 0.01 
- -
0.145 + 0.03 0.1-.2 + 0.03 0.125 + 0.03 
Values represent the Hean + S. E. H. , and are reported as nan0110les IAA. formed /hr. /ug DNA 
Substrate .. ployed was cl4-serotonin 
.... 
C'I 
CX> 
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TABLE 31 MAO Activity following preincubation with various •olar concentrations of t3 and for Tarious 
preincubation time intervals 
Molar Concentration 
of T3 
Mo T3 
10-9M 
10-7M 
10-SM 
10-4M 
10-3M 
No Preincubation 
0.224 + 0.02 
-
0.257 + 0.02 
-
0.194 + 0.05 
-
0.149 + 0.03 
-
0.068 + 0.02 
-
0.029 + 0.01 
N=3 for each determination 
Hypothalamus 
Preincubation Times (Minutes) 
15 minutes 30 minutes 
0.207 + 0 .04 0.203 + o.o3 
- -
0.201 + 0.09 0.156 + 0.02 
- -
0.215 + 0.07 0.215 + o.oe 
- -
0.204 + o.oe 0.183 + 0.06 
- -
0.094 + 0.05 0.095 + 0.03 
- -
0.044 + 0.03 0.032 + 0.02 
60 111inutes 
0.192 + 0.04 
0.142 + 0.01 
-
0.151 + 0.01 
-
0.112 + 0.01 
-
0.047 + 0.02 
0.009 + 0.01 
Values represent the MEAN!_ S.E.M., and are reported as nanomoles !AA formed/hr./ug DNA 
Substrate employed was c14-serotonin 
_. 
0\ 
\0 
TABLE 32 MAO Activity following preincubation with various molar concentrations of T3 and for various 
preincubation time intervals . 
Molar Concentration 
of T3 
No T3 
lo-9M 
l0-7M 
l0-5H 
10-4M 
l0-3H 
No Preincubation 
1.121 + 0.18 
1.208 + 0.18 
-
1.281 + 0.17 
1.27 .. + 0.18 
1.005 + 0.17 
-
o.466 + 0.00 
N•3 for each determination 
Corpus StriatUlll 
Preincubation Times (Minutes) 
15 minutes 30 minutes 60 minutes 
1.2 .. 3 + 0 .18 1.38 .. + 0.19 1.313 + 0.19 
- -
1.318 + 0.19 l.398 + 0 .19 1.450 + 0.12 
- -
1.463 + 0.27 1.441 + 0.26 1.377 + 0.17 
-
1.3 .. 7 + 0.16 1.253 + 0.16 1.318 + 0.18 
- -
0.932 + 0.11 0.977 + 0.15 1.019 + 0.31 
-
0.489 + 0.06 0.426 + 0.06 0.622 + 0.17 
Values represent the MEAN!_ s.E.M., and are reported as nanomoles 5-HIAA formed/hr./ug DNA 
Substrate employed was c14-tryptamine 
/ ,J 
.... 
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TABLE 33 MAO Activity following preincubation with various molar concentrations of T3 and for various 
preincubation time intervals 
Molar Concentration 
of T3 
Ho T3 
io-9H 
l0-7M 
l0-5M 
l0-4M 
l0-3H 
No Preincubation 
3.220 + 0.53 
3.609 + 0.36 
-
3.616 + 0.36 
3.331 + 0.34 
-
2.906 + 0.31 
-
1.779 + 0.24 
N=3 for each determination 
Forebrain 
Preincubation Times (Minutes) 
15 minutes 30 minutes 60 minutes 
3.653 + 0.59 3.617 + 0.45 3.641 + o.38 
3.758 + 0.47 3.945 + 0.45 3.886 + 0.37 
- -
3.701 + 0.51 3.819 + o.54 3.813 + 0.42 
- -
3.532 + 0.42 3.506 + 0.43 3.547 + 0.39 
- -
2.803 + 0.49 2.994 + 0.43 3.174 + 0.38 
-
1.847 + 0.22 1.724 + 0.20 2.314 + 0.49 
Values represent the MEAN:!:. S.E.H., and are reported as nanomoles 5-HIAA formed/hr./ug DNA 
Substrate employed was c 14-tryptamine 
~ 
-.J 
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TABLE 34 MAO Activity following preincubation with various molar concentrations of T3 and for various 
preincubation time intervals 
Molar Concentration 
of T3 
No T3 
io-9M 
io-7M 
io-SM 
io-4M 
io-3M 
No Preincubation 
1.156 + 0 .26 
1.229 + 0.26 
-
1.235 + 0 .26 
1.257 + 0.23 
-
0.931 + 0.19 
-
0.473 + 0.13 
N•3 for each determination 
Hypothalamus 
Preincubatlon Times (Minutes) 
15 minutes 30 minutes 60 minutes 
1.605 + 0 .33 1.727 + 0.25 1.615 + 0.37 
-
1.653 + 0.31 1.737 + 0.34 1.559 + 0.25 
-
1.815 + 0.40 1.767 + 0.39 1.554 + 0.28 
- -
1.488 + 0.30 1.581 + 0.29 1.555 + 0.23 
- -
1.122 + 0.22 1.114 + 0.22 1.173 + 0.21 
- -
o.534 + 0.11 0.497 + 0.10 0.701 + 0.24 
Values represent the MEAN .!_ S.E.H.,and are reported as nanomoles 5-HIAA formed/hr./ug DNA 
Substrate employed was c 14 -tryptamine 
... 
-..] 
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FIGURE 7 
TITLE: The in vitro effect of various molar concentrations of T3 
on activity of monoamine oxidase from three brain regions 
LEGEND 
Brain homogenates were preincubated with concentrations of 
triiodothyronine (T3 ) from 10-3 to 10-9 H, or without T3, for 60 
minutes (similar results, not depicted here, were obtained when the 
preincubation period was O, 15 or 30 minutes). Monoamine oxidase 
activity was determined by measurement of concentrations of indole 
acetic acid (IAA) formed per hour per microgram of tissue DNA 
following addition of 14c-serotonin to the homogenates. Each 
point illustrated is the mean of three determinations with the 
standard error depicted. 
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TABLE 35 Effect of Trilodothyronine on HAO Activity in Three Brain Regions 
Days of 
Injection 
No Injection 
1 
2 
3 
.. 
5 
6 
7 
8 
Corpus Strlatwa 
Saline T3 
2.151 + 0.26 
3.313 + 0.21 2.647 + 0.29 
2.782 + 0.16 3.317 + 0.33 
- -
3.669 + 0.37 4.339 + 0.61 
-
3.eo0 + 0.23 3.296 + 0.42 
3.550 + 0.27 3.255 + 0.17 
- -
2.835 + 0.16 3.702 + 0.55 
- -
3.406 + 0.24 3.425 + 0.40 
3.012 + 0.22 2.709 + 0.47 
- -
Forebrain 
Saline T3 
2.968 + 0.18 
3.741 + 0.56 3.716 + 0.11 
3.077 + 0.25 3.259 + 0.29 
- -
4.217 + 0.68 4.843 + 0.54 
-
3.932 + 0.53 3.510 + 0.29 
-
4.093 + 0.49 3.353 + 0.36 
-
3.593 + 0.30 3.817 + 0.15 
-
4.050 + 0.45 3.884 + 0.44 
4.888 + 0.82 4.750 + 0.69 
-
N=6 for each determination, no statistical significance was observed 
Hypothalamus 
Saline T3 
2.147 + 0.18 
1.810 + 0.15 1.711 + 0.05 
-
1.952 + 0.21 1.981 + 0.18 
- -
2.795 + 0.20 2.607 + 0.43 
- -
2.703 + 0.27 2.111 + 0.31 
- -
2.590 + 0.29 2.276 + 0.13 
-
2.092 + 0.13 2.697 + 0.11 
-
2.640 + 0.29 2.422 + 0.14 
-
2.038 + 0.21 24109 + 0.27 
Values represent the MEAN :!:. S.E.M., and a.re reported as nanomoles 5-HIAA formed/hr./ug DNA 
Substrate employed was cl4-tryptamine 
All animals were sacrificed 24 hours after the last T3 injection 
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TABLE 36 Effect of Thyroxine (T4) on MAO Activity in Three Brain Regions 
Days of 
Injection 
No Injection 
1 
2 
3 
4 
s 
6 
7 
8 
Corpus Striatum Forebraln Hypothalamus 
Saline T4 Saline T4 Saline T4 
0.345 + 0.05 2 .968 + 0.18 2.147 + 0.18 
-
0.933 + 0.21 0.969 + 0.29 0.871 + 0.14 0.889 + 0.23 0.675 + 0.11 0.531 + O.ll 
- - -
o.420 + 0.06 o.548 + 0.01 0.454 + 0.04 0.613 + 0.10 0.274 + 0.04 0.346 + 0.02 
-
0.425 + 0.02 0.342 + 0.06 o.529 + o.o5 0.561 + 0.05 0.255 + 0.02 0.293 + 0.04 
- -
0.464 + 0.03 0.374 + 0.04 o.589 + 0.11 0.433 + 0.03 0.259 + 0.03 0.233 + 0.01 
- -
0.359 + 0.10 0.292 + 0.01 o.506 + o.o3 0.625 + 0.11 -.262 + 0.04 0.284 + 0.04 
0.354 + 0.11 0.330 + 0.05 o.401 + o.oe 0.387 + 0.05 0.244 + 0.05 0.251 + 0.06 
- -
0.618 + 0.04 0.518 + 0.05 0.641 + 0.05 o.738 + o.13 0.535 + 0.11 0.375 + 0.03 
- - -
o.345 + 0.06 0.295 + 0.06 o.585 + o.13 0.494 + 0.17 0.271 + 0.06 0.209 + 0.06 
-
N•6 for each determination 
Hean!. S.E.M.; Nmoles IAA formed/hr./ug DNA; ser-otonin as substrate 
All animals were sacrificed 24 hours after the last T4 injection 
No statistical significance was observed 
:.J 
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TABLE 37 Effect of Thyroxine (T4) on HAO Activity in Three Brain Regions 
Corpus Striatum Forebrain Hypothalamus 
Saline T4 Saline T4 Saline T4 
Days of 
Injection 
No Injection 2.151 + 0.26 
-
2.716 + 0.20 1.926 + 0.17 
l 2.161 + 0.19 2.241 + 0.21 2.101 + 0.15 2 .184 + 0.17 1.554 + 0.15 1.373 + 0 .21 
- -
2 2.043 + 0.34 2.124 + o.52 4.894 + 1.27 3.202 + 0.59 2.128 + 0.36 2.048 + 0.20 
- - - - -
3 2.886 + o.o9 2.415 + 0.35 3.468 + 0.38 3.477 + 0.41 2.194 + 0.25 2.263 + 0.22 
- - - -
4 2.954 + 0.22 2.758 + 0.24 3.969 + o.65 3.452 + 0.35 2.253 + 0.28 2.162 + 0.17 
-
5 2.197 + 0.53 1.691 + 0.25 3.394 + 0.28 3.474 + 0.22 1.900 + 0.39 l.938 + 0.20 
- - -
6 1.792 + 0.28 1.557 + 0.11 2.321 + 0.23 2.009 + 0.00 1.619 + 0.14 1.256 + 0.19 
- - -
7 1.917 + 0.13 1.365 + 0.18 2.190 + 0.16 2.847 + 0.33 1.450 + 0.24 1.095 + 0.11 
- - -
8 1.725 + 0.18 1.482 + 0.13 2.966 + 0.25 2.460 + 0.51 1.518 + 0.14 1.274 + 0.28 
N•6 for each determination 
MEAN!. S.E.M.; Nmoles 5-HIAA fonned/hr./ug DNA; cl4-tryptamine as substrate 
All anillals were sacrificed 24 hours after the last T4 injection . 
No statistical significance was observed 
.... 
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TABLE 38 Morepinephrine Pool Size Levels 
Condition Corpus Striat\DD Forebrain HyPOthalamus 
Controls (saline) 0.954 + 0.04 0.459 + 0.03 3.573 + 0.23 
(N=l2) (N=l2) (N=70) 
T3 - treated 0.827 !.. 0.11•,•• 0 .421 + 0. 04*** 2.828 + 0.135* 
(lag/kg/day - 7 days) (N=l2) (N=l2) (N=31) 
Thyroidectomized 1.379 + 0.13 0.719 .!. 0.03•~,··· 3.396 + 0.27 
(at 7 wks., 8 wks. (N=l2) 
prior to sacrificed) 
Sham Operated 1.221 + 0.13 
(N=l2) 
* p( 0.01 from Tx 
** P< 0.01 from Sham 
**~ p (. O. 01 from controls 
(N=l2) (N=l2) 
0.521 + 0.03* 3.139 + 0.34 
(N=l2) (N=l2) 
TABLE 39 Numerical values for NE levels in hypothalamus following 
alpha-11ethyl-para-tyrosine administration and sacrificed 
three hours after the administration of alpha-methyl-
para-tryosine. Data shown graphically in Figure 9. 
Dosage of MT NE Level Number of Animals 
No MT Mean 3 .3759 N=9 
S .D. 0.4112 
S.E.M. 0.2444 
200 mg/kg Mean 1.9865 N=S 
S.D. 0 .2679 
S.E.M. 0.0947 
400 mg/kg Mean 1.5639 N=9 
S.D. 0.3326 
S.E.M. 0.1109 
600 mg/kg Mean 1.1204 N=3 
S.D. 0.3554 
S.E.M. 0.2052 
800 mg/kg Mean 1.5911 N=3 
S.D. 0 .3798 
S.E.M. 0.2193 
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TABLE 40 Alpha-methyl-para-tyrosine dose response curYe for tri-
iodothyronine treated aniaals. 
Corpus Striatum Forebrain Hypothalamus 
0 Time MEAN 0.5821 0.2421 2.4926 
No MT S.D. 0.1580 0.0648 0.3632 
S.E.M. 0.0912 0.0374 0.2097 
N::3 N::3 N::3 
200 mg/kg 0.3017 0.2390 1.8375 
3 hr. pt. 0.1047 0.108'4 0.2274 
0 .0524 0 .0542 0 .1137 
N::4 N::4 N::4 
400 mg/kg 0.3255 0.2090 1.2367 
3 hr. pt •. 0 .2242 0.1211 0.5095 
0.1294 0.0699 0.12942 
N::3 N::3 N::3 
600 mg/kg 0 .3140 0.1668 1.4371 
3 hr. pt. 0.1126 0.0768 0.8366 
0.0650 0.0443 0.4830 
N::3 N::3 N::3 
800 mg/kg 0.2405 0.3303 l. 7169 
3 hr. pt. 0.1811 0 .1075 l.2052 
0.1102 0.0621 0.6959 
N::3 N::3 N=3 
' ' 
TABLE 41 Turnover of Norepinephrine in the hypothalamus. corpus striatum and forebrain for control 
rats following administration of 400 mg/kg of alpha-methyl-para-tyrosine 
TISSUE TIME (hours after MT administration) 
No MT 1.0 2.0 3.0 4.5 6.0 9.0 
Conpua Striatum 
MEAN o.6978 0. 5883 0. 5781 0 .4709 0.4292 0.3238 0.3080 
S.D. 0.1767 0.1400 0.0870 0.2087 0.1086 0.0882 0.1241 
S.E.M. 0.0721 0 .0572 0.0389 0 .0852 0 .0486 0.0360 0.0439 
Foretrain 
MEAN 0 .4536 0.2644 0.1940 0.1419 0.1780 0.1998 0.1592 
S.D. 0.0747 0.0458 0.0972 0.0311 0.0482 0.0887 0.0479 
S.E.M. 0.0305 0.0187 0.0436 0.0169 0.0197 0.0362 0.0169 
Hypothalamus 
MEAN 3.4047 2.9928 2.1869 1.4213 0.8212 0.8001 0.6264 
S.D. 0.9982 0.6084 0.4625 0.3837 0.5195 0.2608 0 .1573 
S.E.H. 0.4075 0.2721 0.1888 0.1269 0.2121 0.1166 0!0556 
N=6 for each point 
slope for hypothalamus = -0.6074 linear regression coefficient (r 2 )= 0.9825 
slope for corpus striatum = -0.0587 = 0.9680 
slope for forebrain =-0.1298 = 0.9347 
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TABLE 42 TurnovC' of Norepinephrine in hypothalamus, corpus striatwn and forebrain for rats treated with 
triiodothyronine (T3) (lmg/kg/day - 7 days). HT - 400 mg/kg 
TISSUE TIME (hours after MT administration) 
NO MT 1.0 2.0 3.0 4.5 6.0 
Corpus Striatwn 
HEAN 0 .8971 0.8703 0 .6821 0.4447 0.6505 0.6938 
S .D. 0.0966 0.3074 0.2066 0.1375 0.1440 0.2251 
S.E.M. 0.0394 0.1375 0.0924 0.0687 0.0644 0.1007 
Forebrain 
MEAN 0.4498 0.3222 0.2767 0.2307 0.2086 0.1717 
S.D. 0.1320 0.0606 0 .0778 0 .0340 0.0510 0.0742 
S.E,M. 0.0539 0.0271 0 .0345 0 .0170 0.0255 0.0332 
Hypothalamus 
MEAN 2.8280 2 .4068 2 .4474 1.8941 1.6823 1.2003 
S .D. 0.7495 0.5586 0.4825 1.0193 0.8231 o.7216 
S.E.M. 0.1346 0.2793 0 .2158 0.5067 0 .3766 0.3227 
N=4 to 6 detenainations for each point 
slope for hypothalamus = -0.2615 linear regression coefficient (r2) s 0.9625 
slope for corpus striatwn = -0.1545 = o.9106 
slope for forebrain = -0.0676 = 0.9350 
.:J 
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FIGURE 23 
TITLE: DNA standard curve 
LEGEND 
Known concentrations of deoxyribonucleic· acid sodium salt 
(l.O, 2.0, 4.0, 8.0 and 12.0~ were added to assay tubes and 
reacted with potassium ferrous cyanide. DNA fluorescence was 
then read on a spectrophotofluorometric with excitation at 
510 A< meters and emission at 400 """meters. 
18J 
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The calculations involved in deteraining the DNA standard Curve 
are listed below. A linear regression was used to determine the re-
gression .coefficient. 
a = 0 
a1 = 
r2 = 
The 
The 
2.9774 = 
7.3235 = 
0.999803 
Hg DNA 
0 
l 
2 
4 
8 
12 
standard 
standard 
intercept (or blank) = 2.98 !_ 0.32 
slope (relative fluorescence units/ug 
7.32 + 0.05 
= regression coefficient 
error of a0 
error of a1 
= 
calculated fluorescence 
2. 9774 
10.3010 
17 .6245 
32.2716 
61. 5657 
90 .8598 
0.3174 
c 0.0514 
Actual fluorescence units Elotted 
0 (Bk) l 2 4 8 
x 3.20 9.92 17.28 32.53 62.29 
s .d. 0.995 l.45 2.12 2.69 2.98 
S.E.M. 0.22 0.33 0.47 0.60 0.67 
DNA) 
12 
90.38 
2.93 
0.66 
At least 12 determinations were perfomed to calculate the MEAN 
+ S.E.M. (N=l2). 
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FIGURE 24 
TITLE: Norepinephrine standard curve for an external norepinephrine 
standard 
LEGEND 
Varying concentrations of NE were added to assay tubes (O.l, 0.2, 
0.3, 0.4 and 0.5 mg). Fluorescence was then recorded on a spectro-
photometer. Each data point represents the MEAN + S.E. for at 
least 3 experimental determinations. The linear regression co-
efficient was 0.9805. 
Data used in 
' Standards: 
O.l ug NE 
0.2 ug NE 
0.3 ug NE 
0.4 ug NE 
0.5 ug NE 
Figure 24 
Relative Fluorescence Units 
HEAN 12.4 
S.D. 1.9 
S.E.M. 1.1 
20.3 
2.3 
1.3 
27 .4 
4.8 
2.8 
34.0 
1.4 
1.0 
47.3 
1.8 
1.3 
N = 3 for all determinations 
y-intercept = 3.23 
slope = 83.5 relative fluorescence units per 
l ug NE standard 
(r2) = 0.9805 
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RELATIVE FLUORESCENCE UNITS 
• 
FIGURE 25 
TITLE: Norepinephrine standard curve for the internal H3-
norepinephrine standard 
LEGEND 
189 
Varying concentratiorsof labelled H3-NE were added to assay tubes 
and allowed to pass over prepared alumina columns and H3-NE 
recovery was recorded. Each data point represents the MEAN+ 
S.E. for at least 3 experimental determinations. The linear regres-
sion coefficient is 0.9955. 
Data used in Figure 25 
Standards: 
3 0.1 ug H -NE 
3 0.2 ug H -NE 
3 0.4 ug H -NE 
3 0.5 ug H -NE 
CPM 
MEAN 411.4 
S.D. 52.2 
S.E.M. 30.l 
739.2 
99.5 
57. 5 
979 .3 
126.5 
73.1 
1234.3 
201.9 
116.5 
1585.0 
466.1 
269.l 
N = 3 for all determinations 
y-intercept = 137.2 
slope = 2842.3 = relative CPM per 1 ug H3-NE 
(r2) = 0.9955 
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FIGURE 26 
TITLE: Turnover of norepinephrine in the hypothalamus of rats 
treated with triiodothyronine (1 mg/kg/day - 7 days) 
and their respective controls 
LEGEND 
192 
Animals were administered alpha-methyl-para-tyrosine and were 
sacrificed O, 1, 2, 3, 4.5 and 6 hours after this MT administration. 
Turnover rates between these two groups, T3 administered (-x-) and 
saline administered (-o-) were significantly different (p<:_0.01) 
when turnover was measured between O time and 3 hours post MT 
administration. Triiodothyronine administered animals exhibited 
decreased NE turnover when compared to respective saline ad-
ministered animals. Fach point represents the MEAN + S.E. for 
at least 5 experimental determinations. 
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TABLE 43 Norepinepl1l'ine turnover in thyroidectomized rats following 400 mg/kg MT administered I.P. 
TISSUE TIME (hours after MT administration) 
No MT 1.0 2.0 3.0 4.5 6.0 9.0 
Corpus Str iatUll 
MEAN 1.2092 0.8718 o.7349 0.3185 o.5460 0.4164 0.6189 
S.D. 0.4222 0.4804 0.3520 0.1924 0.1294 0.1789 0.2966 
S.E.M. 0.1493 0.2149 0.1574 0.0860 0.0528 0.0730 0.1212 
. 
Forebrain 
MEAN 0.6731t 0.3794 0.2831 0 .2469 0.2310 0 .2957 0.2648 
S.D. 0.1123 0.0945 0.0783 o.0347 0.0562 0.2000 0.0774 
S.E.M. 0.0397 0.0423 0.0350 0.0155 0 .0230 0 .0817 0.0316 
Hypothalamus 
MEAN 3.2560 2 .5190 1.2864 1.3817 1.6773 2.0973 2 .0818 
S.D. o. 7005 0.5630 0 .6429 o.5279 0.5145 0.6984 0.9936 
S.E.M. 0.2477 0.2518 0 .2875 0.2361 0.2100 0.2851 0 .4057 
N=S to 8 ani..als for each determination 
slope for hypothalamus = -0.9848 linear regression• coefficient (r2 ) = O .9793 
slope for corpus striatum = -0.2809 s 0.9679 
slope for forebrain = -0.1952 = o.9212 
._._ .., 
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TABLE 44 Ncrepinephrin• turnover in SHAM operated animals following 400 mg/kg MT administered I.P. 
TISSUE TIME (hours after HT administration) 
No MT 1.0 2.0 3.0 4.5 6.0 9.0 
Corpus Striatua 
HEAN l.0213 0.1102 0.6463 0.5988 0.6497 0.3955 0 .6377 
S.D. 0.2135 0.3099 0.1514 0.1367 0.1940 0.3604 0.3000 
S.E.H. 0.0755 0.1265 0.0677 0.0611 0 .0788 0.1471 0.1225 
Forebraln 
MEAN o.5364 0.3206 0.4189 0.5397 0.2106 0.2903 0.2442 
S.D. 0.1211 0.0401 0.0565 0.2082 0 .0780 0.1577 0.1145 
S.E.M. 0.0428 0.0164 0.0253 0.0931 0.0318 0.0644 0 .0467 
Hypothalamus 
MEAN 3.0530 2.2246 1.8903 1.9670 1.1626 1.0477 1.7161 
s.o. 0.6856 0.8266 0.5722 0. 5490 o.5518 o. 7040 0.3216 
S.E.M. 0.2424 0 .3375 0.2336 0.2241 0.2253 0.2874 0.1313 
N=6 for each determination 
slope for hypothalamus = -0.3678 linear regression coefficient (r2) s 0.8891 
slope far corpus striatum = -0.1875 • 0.9631 
slope for forebrain = -0.0728 : 0.9909 
... 
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TABLE 45 Korepinephrine levels in three brain regions following a 
single acute administration of protriptyline or. following 
3 consecutive administrations of protriptyline. All 
196 
animals vere sacrificed 3 hours after the final protriptyline 
injection. 
Brain Region 
One Admin.(acute) 
Corpus Striatum 
Forebrain 
Hypothalamus 
HEAN 
S.D. 
S.E.M. 
Three Admin.(subchronic) 
Corpus Striat\DI MEAN 
Forebrain 
Hypothalamus 
S.D. 
S.E.H. 
Protriptyline Ad.min. 
animals 
0.6682 
0.2106 
0 .0860 
N=6 
0.3812 
0 .0458 
0.0187 
N=6 
2 .8048* 
0.0401 
0.0232 
N=3 
l. 0008 
0.3702 
0.1511 
N=6 
0.4126 
0.3056 
0.1367 
N=5 
3.3400 
0.8197 
0.3347 
K=6 
Saline Admin. 
animals 
0.6862 
0.1803 
0.0901 
N=5 
0.3779 
0.1168 
0.9477 
N=6 
2.8606 
0.7853 
0.3512 
N=5 
0.9781 
0 .2845 
0.1272 
N=5 
0.6490 
0.2320 
0 .0947 
N=6 
4.0169 
1.5751 
0.6430 
N=6 
*Significantly lower than controls when N=70 9 however. the 
difference is not significantly lower than its paired saline 
control. Therefore this diffC'ence may be due to injection 
stress. and .. y not really be a difference. 
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TABLE 46 Horepinephrine levels in three brain·regions following six 
consecutive injections of protriptyline or following 18 
consecutive injectiais of protriptyline. All animals were 
aacrif iced 3 hours after the final protriptyline administration 
Brain Region 
Six Admin.(subchronic) 
Corpus Striatum 
Forebrain 
Hypothalamus 
MEAN 
S .D. 
S.E.M. 
Eighteen Admin.(chronic) 
Corpus Striatum 
Forebrain 
Hypothalamus 
MEAN 
S.D. 
S.E.M. 
Protriptyline Admin. 
animals 
0.9880 
0.2138 
0.0571 
N=l4 
0.5288 
0.1479 
0.0410 
N=l3 
3.3694 
1.2736 
0.3404 
N=l4 
0.7129 
0.3278 
0.1037 
N=lO 
0 .3722 
0.1022 
0.0295 
N=l2 
2.5661 
0. 7011 
0.2114 
N=ll 
Saline Admin. 
animals 
0.8761 
0.3205 
0.0966 
N=ll 
0.4523 
0.1484 
0.0397 
N=l4 
3.7511 
1.1922 
0 .4215 
N=8 
l.0129* 
0 .4671 
0.1408 
N=ll 
0.4114 
0.1515 
0. 0437 
N=l2 
3.5061* 
1.0071 
0.3560 
N=8 
*Difference from protriptyline administered (p ( 0.01) 
f 
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TABLE 47 Korepinephrine depletion in acutely administered protriptyline 
animals 
No MT Admin. 
Hours after MT 
Administration 
1.0 
2.0 
3.0 
&f. 5 
6.0 
MEAN 
S.D. 
S.E.M. 
MEAN 
S.D. 
S.E.M. 
Cr2) = 0.6213 
Slope : -0.1475 
HYPOTHALAMUS 
3.1740 
0.6192 
0.2769 
N=5 
2.5383 
0.8538 
0.3486 
N=6 
3.0440 
0.5972 
0.2671 
N=5 
2.3917 
0.3514 
0.1435 
N=6 
2 .5867 
0.4275 
0.1745 
N=6 
2.0500 
0.2868 
0.1283 
N=5 
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TABLE 48 Norepinephrine depletion in protriptyline treated 
animals (10 mg/kg/day-6 days-S.C.) and then 
administered MT 6 hours after their final pro-
tripty line injection. These animals were then 
sacrificed at various time intervals after MT 
administration. 
TIME after HT administration NE levels 
NO alpha-M-P-tyrosine 
l hour 
2 hours 
3 hours 
slope = -0.2471 
(r2) = 0.8449 
MEAN 
S.D. 
S.E.M. 
2.5106 
0. 7771 
0.3886 
N=4 
2 .2380 
0.5791 
0.2855 
N=4 
1.6192 
0 .4771 
0.2386 
N=4 
1.8607 
0. 7946 
0 .4588 
N=3 
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TABLE 49 Korepinephrine levels in three brain areas of thyroidectomized 
rats and Shall-operated controls following 3 and 6 consecutive 
days of protriptyline administration. Aniaab were aacrif iced 
12 hours after the final protriptyline administration 
Three days of Corpus Stria tum Forebrain Hypothalamus 
Prot. Admin. 
Thyroidec tomized MEAN 0.8411 0.5842 3.3131 
Rats S.D. 0.5734 0.2318 0 .4941 
S.E.H. 0.2341 0.0946 0.2017 
N=B.· N=6 N=6 
Sham-operated 0.0659 0.4851 3.2305 
Controls o.5222 0.1296 0.7209 
0.2132 0.0529 0.2943 
N=5 N=6 N=6 
Six days of 
Prot. Admin. 
Thyroidect0111ized MEAN 0. 7979 0.5909 2.6163 
Rats S.D. CJ.3550 0.1020 0.6866 
S.E.M. 0.1~49 0.0456 0.2803 
N=6 N=6 N=6 
Sham-operated 0.5798 0.4740 2.8174 
Controls 0.2277 0.1230 1.2590 
0.1018 0.0502 o.5140 
N=6 N=6 N=6 
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TABLE 50 Norapinaphrine levels in three brain areas of thyroidectomized 
rats and Sham-operated controls following 12 and 18 consecutive 
days of protriptyline administration. Animals were sacrificed 
12 hours after the final protriptyline injection 
Twelve days of 
Prot. Ad.min. 
Thyroidectomized 
Rats 
Sham-operated 
Controls 
Eighteen days 
of Prot. Admin. 
Sham-operated 
Controls 
HEAN 
S.D. 
S.E.M. 
MEAN 
S.D. 
S.E.H. 
Corpus Striatum Forebrain 
0.9537• 0.4708 
0.3722 0.1085 
0.1520 0 .0485 
N=6 N=6 
l.4290 0.4608 
0.3715 0.0779 
0.1661 0.0332 
N=B N=6 
0.4887• 0.6672 
0 .1717 0.2064 
0.0701 0.0843 
N=S N=6 
0.7275 0.5591 
0.1988 0.1538 
0.0811 0.0626 
N=6 N=6 
*Statistically different from Control p <::_ 0.01 
Hypothalamus 
3.0393 
0 .3806 
0.1702 
N=6 
3.8033 
0.8986 
0.3668 
N=5 
2.9943 
l.1603 
0 .4737 
N=6 
2 .9770 
0.2848 
0.1163 
N=6 
TABLE 51 Alpha-methyl-para-tyrosine dose response curve in animals 
which have received protriptyline chronically (18 days, 
lOmg/kg/day) in the hypothalat11Us 
Dose of MT Hypothalamus 
No HT 
200 mg/kg 
400 mg/kg 
600 mg/kg 
800 mg/kg 
MEAN 
S.D. 
S.E.M. 
MEAN 
S.D. 
S.E.M. 
MEAN 
S.D. 
S.E.H. 
MEAN 
S.D. 
S.E.M. 
MEAN 
S.D. 
S.E.M. 
2.5590 
1.0676 
0.2387 
N=20 
2. 2408 
0 .6440 
0.2880 
N=5 
2.0801 
0.9180 
0.2546 
N=l3 
2.1090 
1. 5431 
0.6299 
N=6 
2.1039 
0.6098 
0.3049 
N=4 
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TABLE 52 Alpha-11ethyl-para-tyrosine depletion curve in animals receiving 18 days chronic protriptyline 
administration (10 mg/kg/day) 
TISSUE TIME (hours after alpha-H-para-tyrosine administration) 
O Time 
No MT 1.0 2.0 3.0 4.5 6.0 9.0 
Corpus Striatua 
HEAN 0.6521 0.6606 0.7868 o.7830 0.4603 0 .4534 0.2960 
s.o. 0.1699 0.1659 0.2212 0 .3246 0.1563 0.1112 0.0483 
S.E.H. o.oe5o 0.0742 0.1106 0.1452 0.0699 0.0699 0.0216 
N1:4 N=S Ns4 N=S N=5 N=5 N•5 
Farebrain 
HEAN o. 2741 0.4021 0.3351 0.2564 0.2250 0 .2375 0.2849 
s.o. 0.0291 0.1545 0 .0785 0.0606 0.0648 0.0297 0.1015 
S.E.H. 0.0168 0.0691 0.0351 0.0271 0.0324 0.0171 0.0454 
N=3 N=S N=5 N=5 N=4 N=3 N=5 
HypothalaJllus 
HEAN 2.4008 2.4572 1.9041 1.8610 1.4058 1.5247 1.0260 
s.o. 0.6864 0.4616 0.5598 0.5120 0.4701 0.6426 0.2227 
S.E.H. 0.3432 0.2665 0.2503 0.2560 0.2102 0.3213 0.1286 
N=4 N=3 N=5 N=4 N=5 N=4 N=3 
*Alpha-methyl-para-tyrosine was administered 3 hours after the final protriptyline injection. 
Corpus Striatum slope = -0.0464 linear regression coefficient (r2) = 0.9384 
Forebrain slope = -0.0113 = 0.8666 
Hypothalmaus slope = -0.1897 = 0.9331 flJ 
0 
w 
.... 
TABLE 53 Norepinephrine depletion in hypothala11Us following administration of yohimbine, in control 
(saline administered) animals 
Dosa1e of Yohiabine TIME (hours after Yohimbine administration) 
0 Tille 1 hour 2.5 hours 5.0 hours 
(No Yonimbine) 
2.0 •g/kg 
MEAN 3.3099 2.6988 3.5365 3.8163 
S.D. 0.5918 0.4708 0.8431 1.8294 
S.E~M. 0.2416 0.2106 0 .3770 0.8181 
N=6 N=5 N=S N=5 
20.0 ag/kg 
MEAN 3.3099 1.6829 1.4616 2.6973 
s.o. o.5918 0.5312 0.1125 1.1293 
S .E .N. 0.2416 0.2656 0.4114 o.5646 
N=6 N=4 N=4 N=4 
I\) 
0 
4::-
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TABLE 54 Norepinephrine turnover in animals receiving saline, followed 
by yohimbine (20 •g/kg) followed by alpha-methyl-para-tyrosine 
(400 mg/kg) 
Controls (saline only) 
l hour after Yohimbine 
admin. 
l hour after HT, 2 hours 
after Yohimbine 
2 hours after MT, 3 hours 
after Yohimbine 
3 hours after MT, 4 hours 
after Yohimbine 
4. 5 hours after MT• 5. 5 hours 
after Yoh.imbine 
6 hours after MT, 7 hours 
after Yohiabine 
MEAN 
S.D. 
S.E.M. 
Hypothalamus 
2.9968 
0. 5840 
0.2920 
l.9212 
0.4589 
0.2294 
N=4 
l.0348 
0.1929 
0.0965 
N=4 
0. 9750 
0 .1249 
0.0559 
N=4 
0 .8724 
0.2391 
0.1069 
N=4 
0.9404 
0.2593 
0.1297 
N=4 
l.0261 
0.3847 
0.1924 
N=4 
TABLE 55 Norepinephrine depletion in hypothalamus of chronically 
protriptyline administered anillals following yohiabine 
administration ( 20 11g/kg). Animals were administered 
yohimbine 3 hours after the final protriptylin• •injection 
18 days Prot. admin., 
no Yohimbine 
18 days Prot., 
sacrificed 5 minutes 
after Yohirabine 
18 days Prot., 
sacrificed l hour 
after Yohimbine 
18 days Prot., 
sacrificed 3 hours 
after Yohimbine 
MEAN 
S.D. 
S.E.M. 
Hypothalamus 
2.9131 
0. 5240 
0.2620 
N=4 
2.8602 
0 .4089 
0 .1828 
N=4 
2 .6571 
2.0500 
l.0250 
N=4 
2.9131 
0 .5240 
0.2620 
N=4 
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TABLE 56 Norepinephrine turnover in hypothalamus of chronic protriptyline 
administered ra.te. followed by yohiabin• administration (20 mg/ 
kg) followed by alpha~H-p-tyrosine administration (400 ag/kg). 
Animals received yohimbine 3 hours after their protriptyline 
injection, and received alpha-H-p-tyrosine·, l hour after the 
yohimbine injection 
18 days Prot. admin. 
18 days Prot., 5 minutes 
after Yohimbine 
18 days Prot., l hour 
after Yohimbine, 5 minutes 
after HT 
18 days Prot., 2 hours 
after Yohilllbine, 1 hour 
after HT 
18 days Prot. 3 hours 
after Yohimbine, 2 hours 
after HT 
18 days Prot • , 4 hours 
after Yohimbine, 3 hours 
aft_. KT 
MEAN 
S .D. 
S.E.H. 
Hypothalamus 
2.9131 
0.5240 
0.2620 
N=4 
2.8602 
0 .4089 
0 .1828 
N=S 
2.6571 
2.0500 
1.0250 
N=4 
l.7741 
o. 7365 
0.4252 
N=4 
l.6614 
0 .3737 
0.1868 
N=4 
l.6025 
0.3163 
0.1581 
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TABLE 57 Comparison of turnover rates, level of statistical 
significance, slope and linear regression coeff i-
cients in both saline and protriptyline treated 
animals. 
Group with 
COMPARISON slope (r2) 
decreased 
Probability turnover 
acute prot. (6') vs. -0.1130 0.1183 0 .6411 N.S. 
----------6 day prot. ( 6') -0.2740 0.2003 
acute prot. ( 6 1 ) VS• -0.1130 0.1183 0.7363 N.S. 
----------18 day prot. ( 6') -0.2903 0.3397 
6 day prot. ( 6') vs. -0.2740 0.2003 0.0549 N.S. 
----------18 day prot. (6') -0.2903 0.3397 
acute prot. ( 24') VS. -0.5423 0.4513 0.9234 N.S. 
----------18 day prot. (24') -0 .1834 0.2035 
acute prot. ( 24') VS. -0.5423 0 .4513 0.8405 N.S. 
----------6 day prot. ( 24') -0.2791 0.8219 
acute prot. ( 3') VS. -0.1402 0.1992 0.6061 N.S. 
----------
18 day prot. ( 3') -0.2344 0.3427 
acute saline (6') vs. -0.6776 0.6881 p <.0 .01 Acute Prot. 
acute prot. (6') -0.1130 0.1132 
6 day saline (6') vs. -0.5324 0. 7393 0.7219 N.S. 
----------6 day prot. (6') -0.2740 0.2003 
18 day prot. ( 6') VS• -0.2903 0.3397 0.6862 N.S. 
----------
18 day saline (6') -0,6138 0.3163 
acute saline (3') vs. -0.6023 0.7283 PJ-0.005 Acute Prot. 
acute prot. (3') -0.1402 0.1992 
acute saline (3') vs. -0.6023 0. 7283 p 40 ,05 Chronic Prot. 
18 day prot. (3') -0.2344 0.3427 
18 day saline (24') vs.-0.6243 0.6699 PLO.OS Chronic Prot • 
18 day prot. (24') -0.1834 0.2035 
6 day prot. (24') VS• -0 .2791 0.8219 0.6095 N.S. 
----------18 day prot. ( 24') -0.1834 0.2035 
. , 
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TABLE 58 A statistical comparison Ct-test) for slope of NE depletion 
cUE"Ves following alpha-methyl-para-tyrosine administration 
Comparison 
saline controls vs. 
acute protriptyline 
saline controls vs. 
T3 admin. (7 days) 
saline controls vs. 
chronic Prot. (18 days) 
thyroidectomized vs. 
Sham-operated controls 
t~yroidectomized vs. 
Ta admin. (7 days) 
thyroidectomized vs. 
acute Prot. 
thyroidectomized vs. 
chronic Prot. 
Statistical Results 
p(. 0 .oos 
p< 0.025 
p < o.oos 
p(0.05 
p < 0.01 
p(0.005 
p(0.005 
These groups 
have decreased· 
turnover 
acute prot. 
Prot. 
Sham 
Prot. 
Prot. 
